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Abstract
Immunoinhibitory cell receptors that can induce a state of T cell exhaustion upon
exposure to tumor antigen include Programmed Cell Death-1 (PD1). Although much
research has been conducted on PD1, global miRNA regulation of PD1 in a cancer model
has not been investigated. We hypothesized that miRNAs exist that can silence PD1 in
vitro and revert symptoms of T cell exhaustion. Eleven miRNAs were discovered with
altered expression between PD1+ and PD1- CD4+ T cells from melanoma-bearing mice.
miR-28 and miR-107 mimics were shown to bind to and silence the 3’UTR of PD1, and
miR-28, miR-150 and miR-107 inhibitors increased PD1 expression. Furthermore, no
changes were observed in anti-CD3e induced proliferation, while miR-28 and miR-107
mimic transfection significantly reduced activation-induced apoptosis. This study is the
first of its kind to discover global miRNA profiles in PD1+ T cells, providing novel
targets for potential use as prognostic and therapeutic markers in melanoma.

Keywords
Programmed Cell Death-1, T cell exhaustion, melanoma, RNA interference, T cells,
microRNA-28, microRNA-150, microRNA-103, microRNA-107

ii

Acknowledgments
With 2 years of my life devoted to my MSc I have received a lot of support for which I
am thankful for. I would like to dedicate this thesis to my supervisors, technician,
committee advisors, co-researchers, and Department of Pathology professors and
administrative staff.
My supervisors were a blessing and provided me with a nurturing environment to
pursue my research interests. Drs. Weiping Min and Xiufen Zheng respected me as a
researcher and granted me independence in my research goals. Their support was
extremely appreciated and made me tremendously happy that I chose to pursue my MSc
in their lab.
Next, I would like to acknowledge Xusheng Zhang, our lab technician that has
provided most of my knowledge in laboratory techniques and has gone above and beyond
to ensure success in my project. I’m quite positive that without his presence I would not
have grown to be the researcher I am today.
Two others that deserve acknowledgement are the members of my advisory
committee, Drs. Jim Koropatnick and Subrata Chakrabarti. Even though the meetings
were far and few between, each word they uttered unequivocally helped shape the
research questions I needed to ask to create a novel project. Their advice also extended
towards my future goals and provided me with an insight into research that aided in my
decision to purse a PhD degree.
As well, throughout my two years in the Min laboratory I have been lucky enough
to meet a multitude of graduate and undergraduate students, postdocs and medical
students and residents that have participated in the adventures of graduate research. This
group of individuals has each had their part in making my graduate journey exciting.
I would also like to acknowledge Drs. Zia Khan and Chandan Chakraborty.
Participating in their journal club and grant writing classes taught me extensive analytical
and critical thinking skills necessary to become an above-and-beyond researcher. Their
teachings granted me a proper transition into the graduate student mindset and helped
shape my thesis in a meaningful way.
Lastly, my acknowledgements would not be complete without mentioning the
wonderful Department of Pathology administrative staff: Tracey, Susan, Kathilyn, Cecille
and Mair. One in particular, Tracey Koning, went above and beyond to answer all the
questions I had about various administrative issues.
I will forever have great memories of all your support and guidance. Having spent
6 years learning at Western University, this group of people has solidified my belief that
the Department of Pathology is the best department at Western.

iii

Table of Contents
Title ...................................................................................................................................... i
Abstract ............................................................................................................................... ii
Acknowledgments.............................................................................................................. iii
Table of Contents ............................................................................................................... iv
List of Tables .................................................................................................................... vii
List of Figures .................................................................................................................. viii
List of Abbreviations .......................................................................................................... x

Chapter 1 ........................................................................................................................... 1
1 Introduction .................................................................................................................... 1
1.1 Melanoma and epidemiology ................................................................................ 1
1.1.1

Current treatment strategies ........................................................................ 2

1.2 T cell exhaustion ................................................................................................... 3
1.2.1

Inhibitory cell receptors linked to T cell exhaustion .................................. 5

1.2.2

Clinical immunotherapies ........................................................................... 7

1.3 Epigenetics ............................................................................................................ 7
1.4 RNA interference and microRNAs ....................................................................... 8
1.5 miRNAs reported in melanoma ............................................................................. 9
1.5.1

Prognostic potential .................................................................................... 9

1.5.2

Therapeutic potential ................................................................................ 10

1.6 microRNAs in T cell exhaustion ......................................................................... 11
1.7 Rationale .............................................................................................................. 11
1.8 Hypothesis ........................................................................................................... 11

iv

1.9 Specific aims ....................................................................................................... 12
Chapter 2 ......................................................................................................................... 13
2 Materials and methods ................................................................................................. 13
2.1 B16F10 cell culture ............................................................................................. 13
2.2 Melanoma mouse model ..................................................................................... 13
2.3 Lymphocyte isolation .......................................................................................... 14
2.3.1

Lymphocyte isolation from lymph nodes ................................................. 14

2.3.2

Lymphocyte isolation from spleen............................................................ 14

2.3.3

Lymphocyte isolation from tumor tissue .................................................. 14

2.4 Flow cytometry and cell sorting .......................................................................... 15
2.5 miRNA extraction and cDNA synthesis ............................................................. 15
2.6 mRNA extraction and cDNA synthesis............................................................... 16
2.7 miRNA array analysis ......................................................................................... 17
2.8 Real-time quantitative PCR ................................................................................. 19
2.9 In silico analysis .................................................................................................. 22
2.10 pmirGLO dual luciferase plasmid ....................................................................... 22
2.10.1 PD1 3’ UTR amplification ........................................................................ 22
2.10.2 Restriction enzyme digestion and ligation ................................................ 24
2.10.3 Amplification and sequencing .................................................................. 24
2.10.4 Plasmid and miRNA mimic transfection .................................................. 25
2.10.5 Dual Luciferase Assay .............................................................................. 27
2.11 Lymphocyte treatment with anti-CD3e and IFNγ ............................................... 28
2.12 T cell transfection with siRNA, miRNA mimics and inhibitors ......................... 28
2.13 Analysis of proliferation and apoptosis using flow cytometry............................ 30
2.14 Statistical analysis ............................................................................................... 31
v

Chapter 3 ......................................................................................................................... 32
3 Results .......................................................................................................................... 32
3.1 PD1 displays increased expression in T cells isolated from lymphoid and
tumor tissue in a B16F10 mouse melanoma model ...................................... 32
3.2 11 miRNAs have altered expression in PD1+CD4+ T cells ................................. 32
3.3 In silico analysis of miRNAs that may bind to the 3’ UTR of PD1, TIM3 and
BTLA............................................................................................................. 35
3.4 miR-28 and miR-107 silence PD1 through its 3’ UTR ....................................... 35
3.5 Anti-CD3e, but not IFNγ, upregulates PD1 and BTLA expression in vitro ....... 46
3.6 miR-28, miR-150, miR-103 and miR-107 show decreased expression after
anti-CD3e treatment ...................................................................................... 53
3.7 miR-28 and miR-107 inhibitors increase PD1 expression in CD4+ T cells in
vitro ............................................................................................................... 53
3.8 miR-28 and miR-107 mimic transfection has no effect on proliferation in
CD4+ T cells. ................................................................................................. 60
3.9 miR-28 mimic transfection reduces anti-CD3e induced early and late
apoptosis in CD4+ T cells .............................................................................. 69
Chapter 4 ......................................................................................................................... 72
4 Discussion .................................................................................................................... 72
4.1 Discussion ........................................................................................................... 72
4.2 Future Directions ................................................................................................. 78
Chapter 5 ......................................................................................................................... 80
5 References .................................................................................................................... 80
Curriculum Vitae ............................................................................................................ 92

vi

List of Tables
Table 2.1 Affymetrix GeneChip 3.0 miRNA Array miRNA probe sequences ................ 18
Table 2.2 Target sequences of miRNA primers for real time qPCR analysis .................. 20
Table 2.3 Primers used in RT-qPCR detection of mRNA levels ...................................... 21
Table 2.4 PD1 3’ UTR primer sequences ......................................................................... 23
Table 2.5 miRNA mimic sequences / miRNA inhibitor targets ....................................... 26
Table 2.6 Small interfering RNA sequences..................................................................... 29
Table 3.1 miRNA candidates that may silence PD1, TIM3 and BTLA in various
combinations ..................................................................................................................... 42

vii

List of Figures
Figure 3.1 CD4+ and CD8+ T cells from lymph nodes, spleens and tumors of B16F10
tumor-bearing mice express significantly more PD1 than T cells from WT mice ........... 33
Figure 3.2 19 miRNAs have significantly altered expression between CD4+PD1- and
CD4+PD1+ T cells isolated from tumor-bearing mice ...................................................... 36
Figure 3.3 Fold changes in miRNA expression between PD1+CD4+ and PD1-CD4+ T
cells determined by the miRNA array and qPCR data ..................................................... 38
Figure 3.4 RT-qPCR confirms 11 significantly up- and downregulated miRNAs
discovered in the microRNA array ................................................................................... 40
Figure 3.5 Candidate miRNA alignment on the 3’ UTRs of PD1, BTLA and TIM3
mRNA. .............................................................................................................................. 44
Figure 3.6 miR-28 and miR-107 bind to and silence the PD1 3’ UTR ............................ 47
Figure 3.7 Anti-CD3e treatment increases PD1 and BTLA expression in a dosedependent manner ............................................................................................................. 49
Figure 3.8 IFNγ treatment has no effect on PD1, TIM3 or BTLA expression ................. 51
Figure 3.9 miR-28, miR-150, miR-103 and miR-107 decrease expression after PD1
upregulation mediated by anti-CD3e binding ................................................................... 54
Figure 3.10 Lipofectamine 2000 demonstrates greater transfection efficiency in T cells
comparted to Lipofectamine ............................................................................................. 56
Figure 3.11 A 2:1 ratio of siRNA (µg):Lipofectamine 2000 (µL) provides the optimal T
cell transfection efficiency and total viability. .................................................................. 58
Figure 3.12 A 2:1 ratio of GAPDH siRNA (µg):Lipofectamine 2000 (µL) results in a
75% knockdown in GAPDH expression 48 hours after transfection ............................... 61

viii

Figure 3.13 miR-28, miR-150 and miR-107 inhibitors increase PD1 expression after T
cell transfection and incubation on anti-CD3e coated plates ............................................ 63
Figure 3.14 miR-28 significantly silences PD1 expression in CD4+ T cells after
transfection and incubation on anti-CD3e coated plates................................................... 65
Figure 3.15 miR-28 and miR-107 have no effect on cell proliferation induced by antiCD3e stimulation .............................................................................................................. 67
Figure 3.16 miR-28 mimic transfection significantly reduces the percentage of cells in
early and late apoptosis caused by prolonged anti-CD3e activation ................................ 70

ix

List of Abbreviations
2-ME

2-mercaptoethanol

APC

Allophycocyanin

B16F10

Mouse melanoma cell line

β-Actin

Beta-actin

Bcl-2

B-cell lymphoma 2

BLIMP-1

PR domain zinc finger protein 1

BRAF

V-RAF murine sarcoma viral oncogene homolog B

BTLA

B and T lymphocyte attenuator

C57BL/6

Mouse strain C57 Black 6

CCND1

G1/S-specific cyclin-D1

CCR7

C-C chemokine receptor 7

CD

Cluster of differentiation

CDK8

Cyclin-dependent kinase 8

cDNA

Complementary DNA

CTLA4

Cytotoxic T-lymphocyte-associated protein 4

c-Myb

Myb proto-oncogene protein

DC

Dendritic cell

DICER

Endoribonuclease dicer

DMEM

Dulbecco's modified eagle medium

DMSO

Dimethyl sulfoxide

DNMT

DNA methyltransferase

dNTP

Deoxyribonucleotide triphosphate

ERK

Extracellular signal-regulated kinases

FADD

Fas-associated death domain
x

FBS

Fetal bovine serum

FITC

Fluorescein isothiocyanate

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GM-CSF

granulocyte macrophage colony stimulating factor

HDAC

Histone deacetylase

HIV

Human immunodeficiency virus

HMGB1

High-mobility group protein B1

IFNγ

Interferon gamma

Ig

Immunoglobulin

IHC

Immunohistochemistry

IL

Interleukin

IRAK1

Interleukin-1 receptor-associated kinase 1

LAMP1

Lysosomal-associated membrane protein 1

LB

Lysogeny broth

LCMV

Lymphocytic choriomeningitis virus

LPS

Lipopolysaccharide

MAD2L1

MAD2 mitotic arrest deficient-like 1

MAPK

Mitogen-activated protein kinase

MCL1

Induced myeloid leukemia cell differentiation protein Mcl-1

MEK

Mitogen-activated protein kinase kinase

miRNA

MicroRNA

mRNA

Messenger RNA

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NK

Natural killer

NKTL

Natural killer/T-cell lymphoma
xi

NY-ESO-1

Cancer-testis antigen

OPTI-MEM

Reduced serum cell culture medium

PBS

Phosphate buffered saline

PD1 / PDCD1

Programmed cell death-1

PDCD4

Programmed cell death protein 4

PD-L1/2

Programmed death-ligand 1/2

PE

Phycoerythrin

PTEN

Phosphatase and tensin homolog

RISC

RNA-induced silencing complex

RNAi

RNA interference

RT-qPCR

Reverse transcription quantitative polymerase chain reaction

SHIP

SH2-containingInositol 5′-Phosphatase

SHP-1/2

Src homology region 2 domain-containing phosphatase-1/2

siRNA

Small interfering RNA

SNORD61

Homo sapiens small nucleolar RNA, C/D box 61

SOCS1

Suppressor of cytokine signaling 1

TAA

Tumor-associated antigen

TGF-β

transforming growth factor beta

TIL

Tumor infiltrating lymphocyte

TIM3

T cell immunoglobulin domain and mucin domain 3

TNFα

Tumor necrosis factor alpha

TRAF6

TNF receptor-associated factor 6

UTR

Untranslated Region

V600E/K

Valine (V) to glutamic acid (E) or lysine (K) at position 600

VEGF

Vascular endothelial growth factor
xii

1

Chapter 1

1

Introduction

1.1 Melanoma and epidemiology
There are three types of skin cancer, which are named from the cells they emerge from:
non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma,
and the deadliest kind known as melanoma [1]. Melanoma begins in melanocytes, the
pigment producing cells in the skin, and is primarily caused through unrepaired DNA
damage from ultraviolet radiation [1]. Melanocytes make up about 5-10% of all skin cells
and, in humans, are distributed as single cells within the basal layer of the epidermis,
while mouse melanocytes are found in the dermis in hair follicles [2]. Each melanocyte is
surrounded by approximately 5 keratinocytes, but maintain contact with up to 40
surrounding keratinocytes through dendritic extensions, thus forming an epidermal
melanin unit [3]. Upon exposure to sunlight, a keratinocyte signals to its connecting
melanocyte to synthesize melanin in vesicles known as melanosomes. These
melanosomes are transported through the dendritic connections to deposit melanin in the
keratinocytes, which protects by cells from UV radiation by absorbing UV photons and
removing highly reactive oxygen radicals [4]. With enough UV radiation, mutations can
occur that cause melanocytes to grow out of control into a tumor. However, since
melanoma can occur in areas of that body that receive little to no sunlight, it is believed
that a combination of environmental and genetic factors lead to the development of
melanoma.
In 2014, it is estimated that there was approximately 6,500 new melanoma cases
and 1,050 melanoma-related deaths in Canada, representing 3% of new cancer cases and
1.4% of cancer deaths [1]. Over the 5 year span from 2006-2010, approximately 8% of
new cancer cases affected 15-29 year old and 6% of new cases in 30-49 year olds were
melanoma diagnoses [1]. Luckily, the five-year relative survival rate for melanoma is
85% and 92% in men and women, respectively [1]. However, melanoma and nonmelanoma skin cancer is the most common cancer in Canada, which accounts for nearly
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the same number of new cases as lung, breast, colorectal and prostate cancer combined,
thus demonstrating a need to conduct further research on all aspects of melanoma
treatment, diagnoses and prevention [1].
The model used in this study was a murine model of metastatic melanoma
developed by subcutaneous injection of B16F10 cells. This cell line was generated in
1975 by intravenously injecting C57BL/6 mice with B16 cells, isolating pulmonary
melanoma nodules and culturing the cells before injection into a new C57BL/6 mice [5].
This process was repeated 10 times to generate the metastatic B16F10 cell line that has
been shown to have increased metastatic ability over parent B16F1 cells [6].

1.1.1 Current treatment strategies
Treatment for melanoma is quite difficult and its history demonstrates a lack of advances
until the past few years. Although early-stage melanoma is easily cured, more advanced
stages are quite refractory to treatment. Before the approval of Ipilimumab in 2011, no
single drug or synergistic treatment demonstrated a significant increase in the overall
survival rate of metastatic melanoma [7]. The first drug approved by the Food and Drug
Administration (FDA) in 1975 for treatment of advanced melanoma was Dacarbazine,
however the overall survival compared to placebo treatment was not significantly
improved [8]. In 1995 interferon-α2b became the first FDA approved immunotherapeutic
agent against stage IIB/III melanoma [9] and in 1998, interleukin-2 (IL-2) became a
second exogenous cytokine treatment for antitumor activity in metastatic melanoma [10].
However, use of these agents resulted in no significant increase in overall survival even
though higher response rates were observed [11]. Over time it was discovered that
mutations in the V-RAF murine sarcoma viral oncogene homolog B (BRAF) acted as a
proto-oncogene in almost 50% of cutaneous melanomas, with the majority, almost 90%,
occurring at codon 600 [12]. In 2011 and 2013, the FDA approved Vemurafenib and
Dabrafenib, respectively, small-molecule inhibitors of V600E and V600K mutations for
treatment of V600-mutated melanoma [13]. Unfortunately resistance develops in many
patients after 6 months, demonstrating the need for newer therapies [14]. Since BRAF
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works by phosphorylating MEK1 and MEK2 in the MAPK/ERK pathway [15], a smallmolecule inhibitor of MEK1 and MEK2, Trametinib, was tested and approved by the
FDA in May 2013 for the treatment of BRAF V600E and V600K [16]. Since January
2014, the FDA has granted accelerated approval of a combination regime of Dabrafenib
and Trametinib, which has published immature data that suggests that the resistance
achieved through BRAF inhibition monotherapy may be curbed with the addition of a
MEK inhibitor [17]. Other targeted therapies that have been approved by the FDA for
other cancers and have recently been studied in melanoma involve tyrosine kinase (c-kit
and bcr-abl) and angiogenesis (VEGF) inhibitors, however the results are not as
promising as BRAF/MEK inhibitors or upcoming immunotherapies [18, 19].
Currently, although localized melanoma and regional lymph node resection is the
standard of care, targeting the immune system provides an indirect method to control
cancer cell growth by potentiating ongoing and inefficient antitumor immune responses
to break tolerance [20]. Since the approval of an anti-CTLA4 antibody in 2011 there has
been a surge of interest in moving the focus of cancer research toward removing
intratumoral immune suppression [20, 21]. This suppression includes the activation of
inhibitory receptors such as CTLA4, PD1, TIM3 and BTLA on T cells that triggers an
immune checkpoint resulting in inhibition of T cells directed against cancer antigens,
thus preventing the immune system from combating the cancer [22]. This phenomenon
has loosely been termed, T cell exhaustion, since these inhibitory receptors bind B7
molecules on antigen presenting cells preventing the activation of the CD28 costimulatory signal or they may bind various ligands on tumor cells creating a state of T
cell anergy.

1.2 T cell exhaustion
T cell exhaustion is when T cells, in response to antigen stimulation, fail to proliferate
and exert effector functions such as cytotoxicity and cytokine secretion. Exhausted T
cells were initially observed in chronic lymphocytic choriomeningitis virus (LCMV)
infection in mice and characterized by sustained expression of programmed cell death-1
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(PD1) [23, 24]. Blockade of the PD1/PD-L1 interaction resulted in reduced spontaneous
apoptosis, enhanced expansion and improved cytokine secretion of the exhausted T cells
[23, 24]. T cell exhaustion also occurs in cancer; PD1 expression is associated with CD8+
T cells in solid tumors and on antigen specific tumor-infiltrating CD8+ T cells [25-27].
Similar to the LCMV model, blockade of PD1/PD-L1 interaction in both humans and
mice resulted in enhanced cytolytic activity of tumor-associated antigen (TAA)-specific
CD8+ T cells and cytokine production of TAA-specific T helper cells when interacting
directly with the tumor [26]. However, it is important to note that reversal of exhausted T
cells does not always result from blockade of the PD1/PD-L1 interaction [27, 28]. Small
interfering RNA (siRNA)-mediated knockdown of PD1 in T cells has shown to enhance
their functions [29, 30], while in other cases siRNA-mediated PD1 knockdown of T cells
did not affect their functions [28]. This indicates that other mechanisms and pathways are
likely involved in T cell exhaustion.
One pathway that may also be involved in T cell exhaustion is the T-cell
immunoglobulin and mucin-domain-containing molecule 3 (TIM3) negative regulatory
pathway. CD4+ and CD8+ tumor infiltrating lymphocytes (TILs) in mice bearing the solid
tumors for colon adenocarcinoma (CT-26), melanoma (B16) and breast cancer (4T1)
coexpress TIM3 and PD1 [31]. More importantly, all TIM3+ TILs co-express PD1 in
these 3 cancer models [31] and TIM3+/PD1+ CD8+ T-cells are more dysfunctional then
TIM3-/PD1+ and TIM3-/PD1- CD8+ T cells as can be seen by a failure to proliferate and
produce IL-2, TNFα, and IFNγ [31-33]. Targeting both pathways with anti-TIM3 [31,
32]/TIM3 fusion protein [33] and anti-PD-L1 antibodies resulted in reversed tumorinduced T cell exhaustion in vitro [32], reduced tumor growth in vivo [31] and reduced
tumor burden and superior survival advantage in vivo [33] in both solid and non-solid
cancers; colon adenocarcinoma [31], melanoma [32] and acute myeloid leukemia [33]. As
well, the reduction of TIM3+PD1- cells was associated with an increased frequency of
TIM3-PD1+ cells, thus, the combinational effect of anti-TIM3 and anti-PD1 in
suppressing melanoma and colon adenocarcinoma growth may lead to the maintenance of
TIM3-/PD1- T cells [34]. Therefore, combined antibody blockade of the PD1/PD-L1 and
TIM3 in cancer has proven to be beneficial in reducing tumor growth and T cell
exhaustion.
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A third pathway that may be involved in T cell exhaustion is the B and T
lymphocyte attenuator (BTLA) negative regulatory pathway. BTLA+/PD1+/TIM3- and
BTLA+PD1+TIM3+ NY-ESO-1–specific CD8+ T cells represent two dysfunctional T-cell
populations, determined by decreased IL-2, TNF, and IFNγ cytokine production over
BTLA-/PD1-/TIM3- and BTLA-/PD1+/TIM3- NY-ESO-1–specific CD8+ T cells [35].
Thus, BTLA+/PD1+/TIM3+ TILs represent the most exhausted TILs in advanced
melanoma. The triple antibody blockade of BTLA, PD1 and TIM3 increased the
proliferative capacity and the frequency of cytokine producing NY-ESO-1–specific CD8+
T cells compared to single and double blockades [35]. Taken together with the fact that
naive T-cells are single or double positive for BTLA and TIM3, and NY-ESO-1+, MelanA+ and Mage-A10+ effector cells interact via larger numbers of inhibitory receptors [22],
combinational blockade of these multiple inhibitory receptors seems to be the most
efficient method to revert T cell exhaustion, stimulate naïve T cell maturity and promote
anti-cancer immunity. So far, Fourcade J et al [32, 35] have found success with their
studies on this combinational blockade in advanced melanoma in vitro; however, no one
has attempted to observe the effects of RNA interference in a synergistic therapy against
the PD1, TIM3 and BTLA pathways.

1.2.1 Inhibitory cell receptors linked to T cell exhaustion
PD1 is a type I transmembrane receptor and a member of the immunoglobin superfamily
[36]. As well, PD1 is a member of the CD28 family of T-cell regulators and is expressed
on the surface of T-cells, B-cells, macrophages and dendritic cells (DCs) [37-40]. PD1
expression is induced upon T cell activation and upon PD-L1 and PD-L2 binding [41].
Receptors such as PD1 function by recruiting tyrosine phosphatases, including SHP-1,
SHP-2 and SHIP, which are responsible for altering various B and T cell responses [3840]. Interaction between PD1 and its ligands PD-L1/PD-L2 are known to inhibit
activation of immune responses by inducing T-lymphocyte anergy and apoptosis [42-45].
PD-L1 is expressed on resting B cells, T cells, macrophages and DCs [37]. The
expression of PD-L1 is further up-regulated on these cells by various stimulation
including anti-IgM, anti-CD40 and LPS for B cells; anti-CD3 for T cells; anti-CD40,
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LPS, IFNy and granulocyte macrophage colony stimulating factor (GM-CSF) for
macrophages; and anti-CD40, IFNy, GM-CSF, IL-4 and IL-12 for DCs [37]. On the other
hand, PD-L2 is rarely expressed on resting cells and hardly induced on B cells and T cells
[37]. PD-L2 can be induced on macrophages with IFNy and IL-4, and induced on DCs
with anti-CD40, IFNy, GM-CSF, IL-4 and IL-12 [37]. IL-4 induces PD-L2 more strongly
than IFNy, while IFNy induces PD-L1 more strongly than IL-4 on macrophages,
suggesting that T-helper type 1 and type 2 responses mobilize PD-L1 and PD-L2
differentially [46].
TIM3 belongs to the TIM family of molecules that in mice contains 8 members
(TIM-1-8) and in humans contains 3 members (TIM-1,3,4) [47]. TIM3 is a novel
transmembrane protein that is expressed on Th1 cells, cytotoxic CD8+ T cells, regulatory
T cells, DCs, macrophages, monocytes, microglia and natural killer (NK) cells in mice
and humans [48-56]. TIM3 was first found to be involved in the regulation of Th1 cellmediated immunity [48-50]. The interaction of TIM3 with its ligand galectin-9 dampens
the response of both IFNγ producing CD4+ Th1 and CD8+ effector T cells, inducing cell
death; in vivo blockade of this interaction results in exacerbated autoimmunity and
abrogation of tolerance in experimental models, thus establishing TIM3 as a negative
regulatory molecule of the adaptive immune system [48-52]. As well, TIM3 is able to
suppress the nucleic acid-mediated innate immune system through interaction with
HMGB1; preventing nucleic acid recruitment into DCs, which is important for antitumor
immunogenicity in tumor microenvironments that release nucleic acids from dying tumor
cells [53].
BTLA is an immunoglobulin domain-containing glycoprotein with two
immunoreceptor tyrosine-based inhibitory motifs, is a third inhibitory molecule of
lymphocytes that associates with SHP-1 and SHP-2 [57]. Depending on the BTLA allele,
BTLA is known to be expressed by CD4+ Th1 cells, CD8+ T cells, B cells, macrophages,
DCs, and NK cells [22, 35, 57-59]. BTLA inhibits T cell proliferation and cytokine
production in vitro and plays a critical role in the induction of peripheral T-cell tolerance
in vivo [57, 58]. In addition, BTLA mediates the negative regulation of CD8+ T-cell
homeostasis and proliferation in vivo [59].
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1.2.2 Clinical immunotherapies
It is widely believed that blocking these negative regulatory molecules in cancer may
attenuate tumor growth. Ipilimumab, a human monoclonal antibody against CTLA4, was
approved by the FDA in March 2011 to be used on late stage melanoma [60, 61]. Studies
on anti-PD1 antibodies (Nivolumab, Lambrolizumab and Pidilizumab) in various cancers
including melanoma have entered stage 2-3 trials since late 2008 [60, 61]. Currently, no
clinical studies are currently being conducted on TIM3 or BTLA antibodies against any
cancer. Interestingly, some immunotherapies are being tested that block the PD1 ligand
on the tumor cell, which has the benefit of potentiating the antitumor response at a tumorspecific level [61]. Ultimately, research on blockade of the PD1/PD-L1 axis holds much
promise, with greater response rates and lower toxicity due to their tumor-specific mode
of activation, rather than generalized suppression of T cell inhibition [62]. A review on
the 3 anti-PD1 and 4 anti-PD-L1 antibodies currently in clinical trials shows encouraging
responses rates between 20%-50% that have continued responses after treatment and
transient low-grade immune-related adverse effects [63].

1.3 Epigenetics
Epigenetics can be defined as regulatory changes that modulate gene expression without
changing the DNA sequence itself [64]. Modulation can occur by altering chromatin
structure through DNA methylation or histone modification, or further downstream by
regulating messenger RNA (mRNA) through non-coding RNAs such as microRNAs
(miRNAs) [64, 65]. The beautiful aspect between the concept of epigenetics and genetics
is that the former may be therapeutically intervened with greater ease [64]. Currently, a
few therapies that affect DNA methylation and histone modification have been approved
by the FDA: DNA methyltransferase (DNMT) inhibitors such as Decitabine and Vidaza,
and histone deacetylase (HDAC) inhibitors such as Vorinostat and Romidepsin [66].
Although these drugs have been approved for acute leukemia and cutaneous T cell
lymphoma [66], recent research has found convincing evidence for the role of epigenetics
in future treatments of melanoma such as using histone deacetylase inhibitors and IL-2
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[67]. Although miRNAs currently may not have as bold of a therapeutic approach as
DNMT or HDAC inhibitors, the possibility exists and also extends to diagnostic and
prognostic markers.

1.4 RNA interference and microRNAs
One potential mechanism by which PD1, TIM3 and BTLA synthesis can be modulated is
by the induction of miRNAs. miRNAs are short (approximately 22 nucleotides) RNAs
that regulate gene expression by base pairing with the 3’ untranslated regions (UTR) of
mRNAs resulting in the translational inhibition or mRNA degradation [68]. Lin-4 was the
first miRNA discovered in 1993, in the orgasm caenorhabditis elegans [69, 70] and five
years later it was reported that exogenous double stranded RNA can silence genes
through a mechanism termed RNA interference (RNAi) [71]. In 1999, the concept of
RNAi was further understood when silencing in plants was correlated to small RNAs that
match the sequence of the silenced transcript [72]. By 2001, two categories of small
RNAs were classified under an RNAi role: miRNAs and siRNAs. miRNAs are known as
regulators of endogenous genes and are expressed endogenously, while siRNAs protect
our genome by reacting to foreign or invasive nucleic acids and are primarily exogenous
in origin [73]. miRNAs do not have perfect complementarity when in the double stranded
stem loop or to the mRNA targets, which allows one miRNA to bind several mRNA
transcripts. siRNAs are perfectly complementary in their double stranded form and to
their single target mRNA, thus resulting in mRNA degradation [74]. Although in rare
cases siRNA that are perfectly matched may not utilize endonuclease activity to degrade
mRNA, but rather silence in a way similar to miRNAs [74].
Now it is believed that over 1000 miRNAs exist in humans that regulate over 30%
of our genome [75]. miRNAs originate from miRNA genes or introns of protein coding
genes and are termed pri-miRNAs upon transcription by RNA polymerase II, resulting in
capped and polyadenylated transcripts [76]. Pri-miRNAs have a stem loop shape and are
processed by an enzyme Drosha, which is an endoribonuclease that cleaves 11 bp from
the bottom of the stem leaving a 22 bp stem loop known as pre-miRNA [68]. From here,
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Exportin-5 transports the pre-miRNA into the cytoplasm for further processing by Dicer
[76]. Dicer cleaves the terminal loop which generates a double stranded RNA that is
approximately 22 base pairs in length and has 3’ overhangs that are two nucleotides in
length [76]. The last step involves separation of the two strands so that one gets
incorporated in the RNA-induced silencing complex (RISC) [77]. The miRNA loaded
RISC complex is then directed towards the 3’ UTR of target mRNAs, thus inducing
repression of protein expression through mRNA degradation or translational inhibition
[77].

1.5 miRNAs reported in melanoma
Over the years, many miRNAs have been linked to melanoma development as either
oncogenic or tumor suppressive miRNAs. miR-195, mir-221, miR-222, miR-193b, miR15b, miR-199a-5p, miR-424, miR-432-5p and the miR-let-7 family act as oncogenic
miRNAs [65, 78-83], while miR-205, miR-26a, miR-34a, miR-125b, miR-18b, miR-573
act as tumor suppressive miRNAs [84-89]. Many other miRNAs have been linked to
melanoma, but this list demonstrates the potential for miRNAs to use be used clinically
for detection, progression, prognosis, and therapy [90]. Although miRNAs such as miR155 and miR-150 are found upregulated in blood samples of patients suffering from
chronic lymphocyte leukemia, it is unknown whether these changes are a result of the
tumor or immune cells [91]. This highlights the importance of looking at specific tissue
and cell types to understanding altered miRNA expression and its suitability for
prognostic or therapeutic markers. As well, some miRNAs may be oncogenic or tumor
suppressive depending on the cancer, such as miR-155 [92, 93], further demonstrating the
need to understand miRNA regulation in specific diseases and cell types.

1.5.1 Prognostic potential
Although much work still needs to be done on prognostic markers in melanoma,
summaries can be seen that highlight miRNAs miR-150, miR-342-3p, miR-455-3p, miR-
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145, miR-155, and miR-497 as predictors of long-term survival of metastatic melanoma
[94]. Another study looked at lymph node metastasis and discovered that miR-191 was
under-expressed and miR-193b was over-expressed in patients with poor melanomaspecific survival [95]. Other studies do exist that have found correlations between
additional miRNAs and how they may affect clinical outcome, thus demonstrating the
need for more research to determine which miRNAs have the best clinical impact
towards long term survival [84, 96, 97].

1.5.2 Therapeutic potential
With the discovery of aberrant miRNA signatures in various diseases states, the idea of
using antagomirs or miRNA mimics to restore miRNA function has become an intriguing
therapeutic concept [98]. Various in vitro and in vivo studies have shown that use of
miRNA mimics and antagomirs to miR-221, miR-222, miR-182, miR34a, miR-16 and
miR-203 may prove beneficial in the treatment of advanced melanoma [79, 99-101].
Some issues that arise with the use of miRNA as a direct therapy involves targeted
delivery methods, off-target miRNA binding effects and miRNA half-life. Although these
issues may prevent the progression of miRNA as direct therapies, the possibility
definitely exists that miRNAs can be used to predict response to various therapies. For
example, Kheirelseif et al. used a microarray to identify a group of miRNAs as predictors
of response to neoadjuvant chemoradiation therapy [102]. Currently, the expression of
PD-L1 using immunohistochemistry (IHC) is used as a predictive biomarker for PD1/PDL1 therapy [63], however no miRNA biomarkers have been reported. By discovering
miRNA biomarkers for use with IHC that can accurately predict therapy response, we can
reduce the cost of cancer treatment by increasing objective response rates and minimizing
the number of cancer patients that need multiple treatments.
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1.6 microRNAs in T cell exhaustion
Overall, little experimental research has been conducted on PD1, TIM3 and BTLA
synergistically in cancer [31-33, 35], and no experimental research has been done to
observe the effects of miRNAs on PD1, TIM3 and BTLA in melanoma and T cell
exhaustion. Therefore, this study will provide valuable epigenetic data on the
immunoinhibitory target, PD1, which supports the use of miRNAs as prognostic markers
and therapeutic molecules to confer T cell immunity against melanoma.

1.7 Rationale
Currently, the immunotherapy using Ipilimumab is recommended at 4 cycles of 3 mg/kg
per dose given every 3 weeks, which costs approximately $120,000 [103]. This large cost
is a major hurdle for the use of new immunotherapies. It may inhibit the use of new
therapies that seek to combine antibodies against the PD1 and CTLA4 pathway that are
currently in clinical trials [63], as well, as any other combination of immunotherapy and
cancer targeting antibody. By understanding altered miRNA expression in PD1+ T cells I
hope to, for the first time, discover miRNAs that may target PD1 and have potential to be
used as a synergistic therapy against multiple immunoinhibitory receptors.

1.8 Hypothesis
I hypothesize that miRNAs exist that can silence PD1 and potentially other inhibitory
immunoreceptors such as TIM3 and BTLA. As well, that miRNA mimics in vitro can act
therapeutically to revert symptoms of T cell exhaustion.
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1.9 Specific aims
The following 4 specific aims were chosen to test my hypothesis:
1. To discover altered miRNA expression between PD1+ and PD1- T cells in
melanoma-bearing mice
2. To determine the PD1 silencing ability of candidate miRNAs using miRNA
mimics and inhibitors
3. To discover if the silencing candidate miRNAs affect CD4+ T cell proliferation
and apoptosis in vitro.
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Chapter 2

2

Materials and methods

2.1 B16F10 cell culture
To investigate the miRNA regulation of PD1 in T cells in the context of melanoma,
B16F10 mouse melanoma cells were used. B16F10 cells were obtained from ATCC
(Manassas, VA). Cells were cultured using DMEM medium (Gibco, Life Technologies,
Burlington, ON) made complete with 10% fetal bovine serum (FBS; Gibco), 100
units/mL of penicillin (Gibco) and 100 µg/mL of streptomycin (Gibco) at 37 °C in 5%
CO2. B16F10 cells were cultured and passaged in tissue culture flasks for at least 4
passages, and were grown to approximately 80% confluency before each experiment was
performed.

2.2 Melanoma mouse model
8-10 week old C57BL/6 mice (Charles River Canada, Saint-Constant, Canada) were used
to generate a melanoma mouse model. Animals were housed under conventional
conditions at the Animal Care Facility, Western University, and were cared for in
accordance with the guidelines established by the Canadian Council on Animal Care.
Tumors were generated on the backs of each mouse through subcutaneous injection of
4x105 B16F10 cells in phosphate buffered saline (PBS; Gibco). Tumors were allowed to
grow for 16 days or until reaching a size of 2,000 mm3. Mice were monitored daily and
sacrificed using CO2 in accordance with the guidelines established by the Canadian
Council on Animal Care.
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2.3 Lymphocyte isolation
2.3.1 Lymphocyte isolation from lymph nodes
Lymph nodes were obtained from wild-type (WT) and tumor-bearing mice. Single cell
suspensions were generated by pressing lymph nodes through a 40 µm Falcon Cell
Strainer (VWR, Mississauga, ON) into RPMI 1640 medium (Gibco), and cells were
counted and centrifuged for 5 minutes at 1,500 rpm and 4 °C. Depending on the
experiment, cells were resuspended in: PBS with 2% FBS; Complete RPMI 1640
medium, made complete with 10% FBS and 500 units of penicillin and 500 µg of
streptomycin; or Transfection RPMI 1640, composed of 10% FBS and 50mM 2mercaptoethanol (2-ME; Gibco)

2.3.2 Lymphocyte isolation from spleen
Spleens were obtained from WT and tumor-bearing mice. Each spleen was pressed
through a 40 µm Falcon Cell Strainer into RPMI 1640 medium. The cells were loaded
onto 5 mL of Ficoll-Paque (Fisher Scientific, Ottawa, ON) and centrifuged for 25
minutes at 2300 rpm and 20 °C with low acceleration and no deceleration. The middle
lymphocyte layer was transferred and resuspended into a fresh tube of RPMI 1640. Cells
were counted and centrifuged for 5 minutes at 1,500 rpm and 4 °C. Finally, the cells were
resuspended in PBS with 2% FBS.

2.3.3 Lymphocyte isolation from tumor tissue
Tumor tissue was obtained from B16F10 tumor-bearing C57BL/6 mice. The tumor tissue
was digested in Collagenase IV (Life Technologies) for 30 minutes at 37 °C, while being
vortexed every 10 minutes, and then was pressed through a 40 µm Falcon Cell Strainer
into RPMI 1640 medium. Cells were stained with antibodies from the Pan T Cell
Isolation Kit II (Miltenyi Biotec, MA, USA) as per the manufacturer’s instruction and run
through a magnetic MACS column to isolate unstained T cells. Cells were counted and
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centrifuged for 5 minutes at 1,500 rpm and 4 °C before resuspension in PBS with 2%
FBS.

2.4 Flow cytometry and cell sorting
Flow cytometry was performed using a BD LSR II (BD Biosciences, Mississauga, ON)
and cell sorting with a BD FACS Aria III (BD Biosciences, Mississauga, ON). One
million cells were suspended in 100 µL of PBS with 2% FBS and stained with 0.2 µg of
CD3-FITC, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE, BTLA-APC, Rat
IgG2b Isotype Control-PerCP-eFluor 710, Mouse IgG2a K Isotype Control-PE, Mouse
IgG1 K Isotype Control-APC (eBioscience, San Diego, CA) or 0.1 µg of Fixable
Viability Dye eFluor 506 (eBioscience) for 30 minutes at 4 °C. Cells were washed with 2
mL of PBS with 2% FBS, centrifuged for 5 minutes at 1,500 rpm and 4 °C, and
resuspended in the same medium before flow cytometric analysis and sorting.

2.5 miRNA extraction and cDNA synthesis
The miRNeasy Mini Kit (Qiagen, Toronto, ON) was used to isolate total RNA including
miRNAs. 700 µL of QIAzol Lysis Reagent was added to lymphocyte cell pellets and
homogenized by vortexing. After 5 minutes of incubation at room temperature, 140 µL of
chloroform was added and the tube was shaken vigorously for 15 seconds and incubated
at room temperature for 3 minutes. The mixture was centrifuged at 12,000 x g for 15
minutes at 4 °C. The upper aqueous phase was transferred to a new tube and mixed with
1.5 times the volume of 100% ethanol. 700 µL of the mixture was filtered through an
RNeasy Mini Column at 12,000 x g for 15 second, discarding the flow through. 700 µL
of Buffer RWT, and two washes of 500 µL of Buffer RPE were filtered through the
column with centrifugation. 50 µL of RNase free water was used to elute the total RNA
with centrifugation at 12,000 x g for 2 minutes. RNA concentration was measured using a
NanoDrop ND-1000 (Thermo Scientific, Ottawa, ON).
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200 ng of total RNA was used with the miScript II Reverse Transcriptase Kit
(Qiagen). In 200 µL tubes, RNA and water were combined to 12 µL and 4 µL of 5x
miScript HiSpec Buffer, 2 µL of 10x Nucleic Mix and 2 µL of Reverse Transcriptase
Mix was added for a total volume of 20 µL. Tubes were incubated at 37 °C for 60
minutes and then the reverse transcriptase was inactivated with incubation at 95 °C for 5
min. cDNA was placed on ice prior to use in reverse transcription quantitative
polymerase chain reaction (RT-qPCR).

2.6 mRNA extraction and cDNA synthesis
Total RNA was extracted from cells using 0.5 mL of Trizol reagent (Invitrogen,
Burlington, ON). 250 µL of chloroform was added and mixed vigorously, and the
mixture was incubated for 5 min at room temperature before centrifugation at 12,000 x g
for 15 minutes at 4 °C. The aqueous layer was removed, mixed with 0.5 mL isopropanol
and mixed vigorously before incubation for 10 minutes at room temperature. A pellet was
formed after centrifugation at 12,000 x g for 10 minutes at 4 °C and washed with 0.5 mL
of 75% ethanol. After washing, pellets were air dried and resuspended in RNase free
water (Life Technologies) and incubated for 10 minutes at 60 °C. RNA concentration was
measured using a NanoDrop ND-1000.
2 µg of mRNA was used for reverse transcription. First, 15.5 µL RNA in RNase
free water and 1 µL oligo-(dT) (0.5µg/µL) were mixed and incubated at 70 °C for 10
minutes. 2 µL of 10x 1st strand buffer, 1 µL of 10mM (deoxyribonucleotide
triphosphates) dNTPs and 0.5 µL of reverse transcriptase (100 units) (Invitrogen) were
added to the reaction mixture. The tube was incubated at 42 °C for 50 minutes and
reverse transcriptase was inactivated at 70 °C for 15 minutes. Finally, cDNA was placed
on ice before use in RT-qPCR.

17

2.7 miRNA array analysis
The Affymetrix GeneChip 3.0 miRNA Array (Affymetrix, Santa Clara, CA) was used
with the FlashTag Biotin HSR RNA Labeling Kit (Affymetrix). To begin, a poly(A) tail
was added to each RNA strand. 500 ng of total RNA containing miRNAs was adjusted to
8 µL in nuclease-free water. Next, 2 µL of RNA Spike Control Oligos was added and the
tube was placed on ice. A master mix was made that consisted of the following reaction
mixture per RNA sample: 1.5 µL 10X Reaction Buffer, 1.5 µL 25 mM MnCl2, 1.0 µL
Diluted ATP Mix and 1.0 µL Poly A Polymerase Enzyme. The 5 µL of master mix was
added to the 10 µL RNA/Spike Control tube for a final volume of 15 µL. The mixture
was spun down in a microfuge and incubated at 37 °C for 15 minutes.
After addition of a poly(A) tail, the RNA was tagged with Biotin-labeled RNA. 4
µL of 5X FlashTag Biotin HSR Ligation Mix and 2 µL of T4 DNA Ligase was added to
each 15 µL poly(A) RNA sample. The tube was mixed by pipetting, microcentrifuged
and incubated at room temperature for 30 minutes. After, the reaction was stopped by
adding 2.5 µL HSR Stop Solution and the solution was mixed by pipetting and
microcentrifuged. 2 µL was removed to confirm quality using the Enzyme Linked
Oligosorbent Assay (Affymetrix)
The next step involved hybridizing the biotin-labelled RNA to the miRNA array.
The hybridization cocktail was made by mixing the following reagents: 66 µL 2X
Hybridization Mix, 19.2 µL 27.5% Formamide, 12.8 µL DMSO, 6.6 µL 20X
Hybridization Controls, 2.2 µL Control Oligo B2 (3 nM) and 3.7 µL nuclease-free water
for a total volume of 110.5 µL. The 110.5 µL hybridization cocktail was added into the
remaining 21.5 µL of biotin-labeled RNA. The final mixture was incubated at 99 °C for 5
minutes, followed by another 5 minute incubation at 45 °C. The 130 µL mixture was
injected into the Affymetrix GeneChip 3.0 miRNA Array and the arrays were loaded into
a preheated Affymetrix Hybridization Oven 645 (Affymetrix) at 48 °C and 60 rpm for 16
hours. A list of probes sequences on the miRNA array for the various miRNAs studied in
this project are listed in Table 2.1.
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Table 2.1 Affymetrix GeneChip 3.0 miRNA Array miRNA probe sequences
Mature miRNA
miR-103
miR-107
miR-146a
miR-150
miR-151-5p
miR-155
miR-181a
miR-21
miR-23a
miR-27a
miR-28
miR-30b
miR-378b
miR-466c-5p
miR-467a
miR-5121
miR-669a-3p
miR-669a-5p
miR-let-7e

Probe Sequence (5’  3’)
TCATAGCCCTGTACAATGCTGCT
TGATAGCCCTGTACAATGCTGCT
AACCCATGGAATTCAGTTCTCA
CACTGGTACAAGGGTTGGGAGA
ACTAGACTGTGAGCTCCTCGA
ACCCCTATCACAATTAGCATTAA
ACTCACCGACAGCGTTGAATGTT
TCAACATCAGTCTGATAAGCTA
GGAAATCCCTGGCAATGTGAT
GCGGAACTTAGCCACTGTGAA
CTCAATAGACTGTGAGCTCCTT
AGCTGAGTGTAGGATGTTTACA
TCTTCTGACTCCAAGTCCAG
ATATGTACATGCACACACACATCA
CGCATATACATGCAGGCACTTA
GGAGATGTCTCATCACAAGCT
ATACGTGTGTGTGTATGTTATGT
AGACATGAACATGCACACACAACT
AACTATACAACCTCCTACCTCA
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After hybridization, the hybridization cocktail was extracted from each array and
the array was filled with Array Holding Buffer. After equilibrating to room temperate, the
arrays were stained using the Fluidics Station 450 (Affymetrix) with the appropriate
fluidics and fluidics script for the array format.
Lastly, after staining and washing the array was scanned using the GeneChip
Scanner 3000 and Affymetrix GeneChip Command Console software (Affymetrix). The
analysis of miRNA data was performed using the Partek Genomics Suite (Partek, St.
Louis, MO).

2.8 Real-time quantitative PCR
Primers for RT-qPCR detection of significantly altered miRNAs discovered from the
miRNA array are unique in the sense that they extend the cDNA of the miRNA for
detection by quantitative PCR. The primer sequences are not available, but a list of their
targets is displayed in Table 2.2. Real-time PCR reactions were performed in a Stratagene
Mx3000P QPCR System (Agilent Technologies, Lexington, MA) using the miScript
SYBR green PCR Kit (Qiagen) and miScript Primer Assay (Qiagen). The reaction
mixture contained: 10 µL 2x QuantiTect SYBR Green PCR Master Mix, 2 µL 10x
miScript Universal Primer, 2 µL 10x miScript Primer Assay and 6 µL of cDNA mix in
RNase-free water for a total volume of 20 µL. The PCR reaction conditions for miRNA
analysis was 95 °C for 15 min, and 94 °C for 15 seconds, 55 °C for 30 seconds and 70 °C
for 30 seconds (40 cycles). Each miRNA primer was referenced to Homo sapiens small
nucleolar RNA, C/D box 61 (SNORD61) and normalized to PD1- cells using the 2-ΔΔCt as
described by Livak and Schmittgen [104].
qPCR detection of GAPDH silencing in T cells using siRNA was analyzed in a
Stratagene Mx3000P QPCR System (Agilent Technologies, Lexington, MA) with SYBR
Green PCR Master Mix (Life Technologies). The reaction mixture was composed of 10
µL of 2x SYBR Green PCR Master Mix, 100 ng of cDNA, 100 nM primers for GAPDH
and β-Actin (Table 2.3), and RNase-free water brought up to 20 µL. The PCR reaction
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Table 2.2 Target sequences of miRNA primers for real time qPCR analysis
Mature miRNA
miR-103
miR-107
miR-146a
miR-150
miR-151-5p
miR-155
miR-181a
miR-21
miR-23a
miR-27a
miR-28
miR-30b
miR-378b
miR-466c-5p
miR-467a
miR-5121
miR-669a-3p
miR-669a-5p
miR-let-7e
SNORD61

miRNA Target Sequence (5’  3’)
AGCAGCAUUGUACAGGGCUAUGA
AGCAGCAUUGUACAGGGCUAUCA
UGAGAACUGAAUUCCAUGGGUU
UCUCCCAACCCUUGUACCAGUG
UCGAGGAGCUCACAGUCUAGU
UUAAUGCUAAUUGUGAUAGGGGU
AACAUUCAACGCUGUCGGUGAGU
UAGCUUAUCAGACUGAUGUUGA
AUCACAUUGCCAGGGAUUUCC
UUCACAGUGGCUAAGUUCCGC
AAGGAGCUCACAGUCUAUUGAG
UGUAAACAUCCUACACUCAGCU
CUGGACUUGGAGUCAGAAGA
UGAUGUGUGUGUGCAUGUACAUAU
UAAGUGCCUGCAUGUAUAUGCG
AGCUUGUGAUGAGACAUCUCC
ACAUAACAUACACACACACGUAU
AGUUGUGUGUGCAUGUUCAUGUCU
UGAGGUAGGAGGUUGUAUAGUU
GCTATGATGAATTTGATTGCATTGA
TCGTCTGACATGATAATGTATTTTT
GTCCTCTAAGAAGTTCTGAGCTT
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Table 2.3 Primers used in RT-qPCR detection of mRNA levels
Mature miRNA
GAPDH Forward
GAPDH Reverse
Β-Actin Forward
Β-Actin Reverse

miRNA Target Sequence (5’  3’)
TGATGACATCAAGAAGGTGGTGAA
TCCTTGGAGGCCATGTAGGCCAT
AGGGAAATCGTGCGTGACATCAAA
ACTCATCGTACTCCTGCTTGCTGA
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conditions were: 95°C for 10 minutes followed by 40 cycles at 95°Cfor 30 seconds, 58°C
for 1 minute and 72°C for 30 seconds. Relative GAPDH gene expression was calculated
with 2-ΔΔCt using β-Actin as a reference gene.

2.9 In silico analysis
In silico analysis was performed by accessing multiple miRNA databases: miRanda,
TargetScan Mouse 6.2 and PicTar. In each database, miRNAs were searched that had
complementarity to the 3’ UTRs of PD1, TIM3 and BTLA. Only miRNAs that were
7mer or 8mer were considered. There are 2 types of 7mer and 1 type of 8mer binding:
7mer-m8 and 8mer miRNAs bind in positions 2-8 of the seed region and 7mer-1A
miRNAs bind in positions 2-7 in the seed region with position 8 bound to an A on the
mRNA.

2.10 pmirGLO dual luciferase plasmid
2.10.1

PD1 3’ UTR amplification

The 3’ UTR of PD1 was amplified using PCR. cDNA from WT C57BL/6 lymphocytes
were used in a reaction mixture that contained: 19.8 µL nuclease free water, 2.5 µL 10x
PCR buffer, 0.5 µL of 10 µM forward and reverse primer (Table 2.4), 0.5 µL 10 mM
dNTPs, 0.2 µL of 5U/ µL Taq polymerase (Invitrogen) and 1 µL cDNA. Sample was
thermocycled at 94 °C for 3 minutes, and run through 40 cycles at 94 °C for 30 seconds,
58 °C for 30 seconds and 72 °C for 30 seconds before a final incubation at 72 °C for 10
minutes.
The amplified cDNA was run on a 1.5% agarose gel and the QIAquick Gel
Extraction Kit (Qiagen) was used to isolate the DNA from reaction mixture components.
The DNA fragment was excised from the agarose gel and 3 volumes of buffer QG was
added to 1 volume of gel (100 mg ~ 100 µL). After a 10 minute incubation at 50 °C, 1 gel
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Table 2.4 PD1 3’ UTR primer sequences
Primer Name
PD1 3’ UTR Forward
PD1 3’ UTR Reverse

Primer Sequence (5’  3’)
ATATACTCGAGCCAGATTCTTCAGCCATTAGCATG
CT
GCGTGTCTAGATTTAAAGCTTTTGGTACCATTTAA
TTATAACGGGCT
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volume of isopropanol was added to the sample and mixed by inverting the tube. The
sample was applied to a QIAquick column and centrifuged for 1 minute at 12,000 x g.
The flow through was discarded and two washes were done using 500 µL of buffer QG1
and then 750 µL of buffer PE followed by centrifugation for 1 minute at 12,000 x g for
each wash. The QIAquick column was placed in a new Eppendorf tube and 50 µL of
buffer EB was added onto the membrane to elute the DNA.

2.10.2

Restriction enzyme digestion and ligation

500 ng of amplified PD1 3’ UTR and pmirGLO Dual Luciferase Plasmid were cut with
XhoI and XbaI restriction enzymes (New England Biolabs, Ipswich, MA). The plasmid
and PD1 3’ UTR were cut in separate tubes that contained both restriction enzymes. 12
units of each restriction enzyme were used in a total volume of 28 µL consisting of 10x
buffer and nuclease free water. The reaction mixture was incubated at 37 °C for 30
minutes. 50 ng of cut plasmid and 35 ng of cut insert were ligated overnight at 16 °C. The
ligation used a 5:1 molar ratio of insert:vector and a T4 DNA ligase (New England
Biolabs), in a total volume of 20 µL.

2.10.3

Amplification and sequencing

The PD1 3’ UTR pmirGLO Dual Luciferase Plasmid was amplified in JM109 cells
(Promega, Madison, WI). First, JM109 cells were thawed on ice for 5 minutes and mixed
before transferring 50 µL to a chilled sterile polypropylene culture tube. 25 ng of PD1 3’
UTR pmirGLO plasmid was added to the competent cells and placed on ice for 10
minutes. Cells were heat-shocked at 42 °C for 45 seconds, placed on ice for 2 minutes,
added to 450 µL of lysogeny broth (LB; Life Technologies) containing 100µg/mL
ampicillin (Bioshop, Richmond, BC) and were shaken at 37 C° for 60 minutes. All 500
µL was plated on ampicillin containing LB plates overnight, and afterwards clones were
isolated and shaken overnight at 37°C in 5 mL of LB broth containing ampicillin.
Plasmid was extracted using the GeneJET Plasmid Miniprep Kit (Fermentas, Burlington,
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ON). Cells were pelleted in a centrifuge and resuspended in 250 µL of resuspension
solution. 250 µL of lysis solution was added and mixed by inverting the tube, and then
350 µL of neutralization solution was added and mixed by inverting the tube. Cells were
centrifuged for 5 minutes at 12,000 x g. The supernatant was transferred to a GeneJET
spin column and centrifuged for 1 minute at 12,000 x g. The flow through was discarded
and two washes of 500 µL wash solution was added and the column centrifuged for 1
minute at 12,000 x g each time. The plasmid was eluted from the column by adding 50
µL of elution buffer, waiting 2 minutes and centrifuging the columns at t 12,000 x g for 2
minutes. The concentration of the plasmid was then measured using a NanoDrop ND1000.
Sequencing was done using the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA). Initially, 1.5 µg of PD1 3’ UTR pmirGLO
plasmid was brought up to a final volume of 20 µL in nuclease-free water after the
following reaction conditions were added: 8 µL Terminator Ready Reaction Mix and 2
µL of 2µM PD1 3’ UTR forward primer (Table 2.4). The sample was mixed briefly, and
spun down before cycle sequencing was performing on a GeneAmp PCR System 9600
(Applied Biosystems). Tubes were heated to 95 °C for 5 minutes and then cycled 50
times at 95 °C for 30 seconds, 55 °C for 10 seconds and 60 °C for 4 minutes. Tubes were
cooled down to 4 °C before purification of extension products using the Performa DTR
V3 96-Well Short Plate Kit (Edge Biosystems, Gaithersburg, MD). Lastly, sequencing of
purified extension product was performed in an Applied Biosystems 3730 DNA
Analyzer.

2.10.4

Plasmid and miRNA mimic transfection

The list of miRNA mimics (Qiagen) transfected with the PD1 3’ UTR pmirGLO plasmid
are shown in Table 2.5. 60,000 B16F10 cells per well were plated overnight before
transfection in 24 well plates using culture medium. On the day of transfection, cells were
washed with PBS and 300 µL of Opti-MEM was added. In an Eppendorf tube, 0.2 µg of
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Table 2.5 miRNA mimic sequences / miRNA inhibitor targets
miRNA mimic
miR-28
miR-150
miR-103
miR-107
mimic control

miRNA sequence (5’  3’)
AAGGAGCUCACAGUCUAUUGAG
UCUCCCAACCCUUGUACCAGUG
AGCAGCAUUGUACAGGGCUAUGA
AGCAGCAUUGUACAGGGCUAUCA
The AllStars Negative Control siRNA sequence is not
available, but it has no homology to any known
mammalian gene (Qiagen #SI03650318)

inhibitor control

The miRNA inhibitor control sequence is not available,
but it is designed to target the AllStars Negative Control
siRNA and has no homology to any known mammalian
gene (Qiagen #1027271)
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plasmid and 1 µg of miRNA mimic were added to 100 µL of Opti-MEM. In a separate
tube, 100 µL of Opti-MEM was mixed with 2.4 µL of Lipofectamine 2000 Transfection
Reagent (Life Technologies) in a 1:2 ratio of miRNA + plasmid (µg):Lipofectamine 2000
(µL). After 5 minutes of room temperature incubation, both tubes were mixed and
allowed to incubate for 20 minutes at room temperature. Then the 200 µL mixture of
Opti-MEM, miRNA mimic and dual luciferase plasmid was added into each well of
plated B16F10 cells. After 4 hours incubating at 37 °C and 5% CO2, the wells were
topped off with culture medium with 20% FBS and placed back at 37 °C and 5% CO2 for
24 hours before analysis in a Lumat LB 9507 luminometer (Berthold Technologies, Oak
Ridge, TN).

2.10.5

Dual Luciferase Assay

The Dual-Luciferase Reporter Assay System (Promega) was used to detect firefly and
renilla luciferase from the PD1 3’ UTR pmirGLO plasmid. 24 hours after transfection
with plasmid and miRNA mimic, B16F10 cells were washed with PBS in preparation for
lysis. Cells were no more than 95% confluent at the time of lysis. 100 µL of passive lysis
buffer was added to each well and the plate was rocked gently for 15 minutes. The lysate
was transferred to an Eppendorf tube for detection in a Lumat LB 9507 luminometer
(Berthold Technologies). 100 µL of Luciferase Assay Reagent II was predispensed in
polypropylene tubes and 20 µL of cell lysate was added and mixed by pipetting. After a
10 second measurement for firefly luciferase activity, 100 µL of Stop & Glo reagent was
added and the tube was vortexed. The sample was placed back in the luminometer and
renilla luciferase activity was measured for 10 seconds. Each sample was read twice, and
luciferase activity (firefly luciferase/renilla luciferase) was normalized to the miRNA
mimic control and PD1 3’ UTR pmirGLO transfection.
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2.11 Lymphocyte treatment with anti-CD3e and IFNγ
Lymphocytes isolated from lymph nodes of C57BL/6 mice were treated with anti-CD3e
(BD Biosciences) or IFNγ (Peprotech, QC) by plating 2 million cells in 24 well plates.
For treatment with anti-CD3e, the plates were coated with various concentrations (from 0
– 25 µg/mL) of anti-CD3e in 200 µL of PBS overnight at 4 °C. Plates were washed with
PBS before lymphocytes were plated in Complete RPMI 1640. Treatment with IFNγ
involved adding various concentrations (0 – 20 ng/mL) to the well at the time of plating.
With both treatments, lymphocytes were incubated at 37 °C and 5% CO2 for 24 hours
before cells were collected for flow cytometry.

2.12 T cell transfection with siRNA, miRNA mimics and
inhibitors
Lymphocytes from the lymph nodes of WT C57BL/6 mice were plated 2 million per well
in a 24 well plate using 400 µL of RPMI 1640 with 10% FBS and 50 mM 2-ME
(Transfection RPMI 1640 medium). 1 µg of miRNA mimic, miRNA inhibitor (Qiagen)
(Table 2.5) or siRNA (Ambion, Austin, TX) (Table 2.6) was added to 50 µL of OptiMEM and various ratios of transfecting reagent was added to a separate tube with 50 µL
of Opti-MEM. A 2:1, 1:1, 1:2, 1:4 and 1:6 ratio of siRNA (µg):transfection reagent (µl)
was used for the initial experiments on T cell transfections and a 2:1 ratio was used for
the rest. After 5 minutes of room temperature incubation, the RNA and transfection
reagent tubes were combined and incubated for 20 minutes at room temperature. The 100
µL mixture was then added to each well. After 4 hours of incubation at 37 °C and 5%
CO2, 500 µL of Transfection RPMI 1640 was added to each well and the plates were
incubated for up to 48 hours at 37 °C and 5% CO2 before cells were collected for various
experiments.

29

Table 2.6 Small interfering RNA sequences
Gene
GAPDH
control siRNA

siRNA sequence (5’  3’)
The Silencer Cy3-labelled GAPDH siRNA sequence is
not available (Ambion #AM4649)
The negative control siRNA sequence is not available,
but it has no significant homology to any known gene
sequences from mice, rats or humans (Ambion
#AM4611)
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2.13 Analysis of proliferation and apoptosis using flow
cytometry
For functional analysis of CD4+ T cells after miRNA mimic transfection, CD4 MACS
beads (Miltenyi Biotec) were used to purify CD4+ T cells before flow cytometric
analysis. The cells were stained as per manufacturer’s instructions and run through a
magnetic column to positively isolate the CD4+ T cells.
To visualize cell proliferation, lymphocytes were transfected as described in 2.12
and stained with carboxyfluorescein succinimidyl ester (CFSE; eBioscience) prior to
plating on anti-CD3e coated plates. After transfection, cells were suspended 50 x 106
cells/mL in PBS and CFSE was added to a final concentration of 5 µM. Cells were mixed
rapidly to evenly disburse the CFSE and incubated at room temperature for 5 minutes.
Cells were wash with 10 volumes of PBS containing 5% FBS and centrifuged at 1500
rpm and 20°C for 5 minutes. After 3 washes, the cells were resuspended in Complete
RPMI 1640 medium and plated on anti-CD3e coated plates for 4 days before CD4 MACS
bead isolation, PD1 PerCP eFluor 710 staining and analysis by flow cytometry. As cells
proliferate, the CFSE staining gets split to the daughter cells creating a weaker CFSE
signal. Therefore, CFSElow signal peaks were gated to quantify the percentage of
proliferating cells.
To measure apoptosis, cells were transfected as described in 2.12, and stained
with PD1-PerCP-eFluor 710, and Viability Dye eFluor 506 as described in 2.4 after CD4
MACS beads isolation. After PD1 and viability staining, cells were suspended in 100 µL
of Annexin V Binding Buffer (BD Biosciences) and 5 µL of Annexin V-FITC (BD
Biosciences) was added. After a 15 minute incubation at room temperature, 200 µL of
Annexin V Binding Buffer were added and cells were analyzed by flow cytometry. Cells
that double stain for eFluor 506 and Annexin V are in late apoptosis, while cells that only
stain for Annexin V are in early apoptosis. Viable cells stain double negative.
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2.14 Statistical analysis
Either a one-way analysis of variance (ANOVA) or a two-tailed unpaired Student’s T test
was used to determine significance for all experiments. Signification was determined if p
< 0.05. Further details can be found in each figure legend.
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Chapter 3

3

Results

3.1 PD1 displays increased expression in T cells isolated
from lymphoid and tumor tissue in a B16F10 mouse
melanoma model
To develop a B16F10 murine melanoma model, C57BL/6 mice were injected with
400,000 B16F10 cells in two spots on their back and tumors were allowed to grow for 16
days before isolating lymphocytes from the lymph nodes, spleen and tumors. Next, flow
cytometry was performed to determine the PD1 expression profile in T cell-containing
tissues between WT and B16F10 injected mice. PD1 expression was significantly
increased in B16F10 tumor-bearing mice compared to WT mice (Figure 3.1A). On CD4+
T cells, PD1 expression significantly increased in the spleens from B16F10 tumorbearing mice compared to WT lymph node, WT spleen and B16F10 lymph node (Figure
3.1B). CD8+ T cells demonstrated a significant increase in B16F10 spleens over WT
lymph nodes (Figure 3.1B). In the tumor tissue, CD4+ T cells displayed 48.1% PD1
expression while CD8+ T cells displayed 27.45% PD1 expression (Figure 3.1B). Since
only approximately 50,000 T cells could be isolated from each tumor, and CD8+ T cells
express PD1 to a lesser extent, it was decided to sort CD4+ T cells from the lymph nodes
and spleen for microRNA array analysis.

3.2 11 miRNAs have altered expression in PD1+CD4+ T
cells
To analyze the global miRNA expression profile between PD1+ and PD1- T cells,
PD1+CD4+ and PD1-CD4+ T cells were sorted from lymph nodes and spleen using a
FACS Aria III and total RNA including miRNA was extracted. 800 ng of RNA was used
for the Affymetrix GeneChip 3.0 miRNA array. No significant differences were found
between the miRNA expression profiles of either tissue, so data from the both tissues
were pooled. A heatmap was generated looking at miRNAs with a fold change of +/- 2,
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Figure 3.1 CD4+ and CD8+ T cells from lymph nodes, spleens and tumors of B16F10
tumor-bearing mice express significantly more PD1 than T cells from WT mice.
CD4+ and CD8+ T cells were isolated from the lymph nodes and spleen of WT mice and
lymph node, spleen and tumors of B16F10 injected mice. (A) PD1 expression on viable T
cells was analyzed by flow cytometry. (B) A one-way ANOVA followed by a Tukey’s
post-hoc test was used to compare PD1 expression levels between tissues. Signification
was determined if p < 0.05 (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001). The data
shown are representative of at least two independent experiments.
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which found 11 significantly downregulated and 8 significantly upregulated miRNAs in
PD1+CD4+ T cells (Figure 3.2). In order to confirm the results of miRNA array, 200 ng of
RNA was used for real time RT-qPCR analysis on the 19 miRNAs. Figure 3.3 displays
discrepancies between the miRNA array and qPCR data, showing that only 3 down
regulated miRNAs (miR-150, miR-28 and miR-151-5p) and 8 upregulated miRNAs
(miR-let-7e, miR-103, miR-107, miR-27a, miR-23a, miR-21, miR-155 and miR-146a)
showed similar trends in altered miRNA expression levels. miR-28, miR-150 and miR151-5p expression in PD1+CD4+ T cells decreased by 30%, 45% and 25%, respectively
(Figure 3.4A) and miR-let-7e, miR-103 and miR-107 increased by 189%, 328% and
318%, respectively (Figure 3.4B). 5 miRNAs; miR-27a, miR-23a, miR-21, miR-155 and
miR-146a displayed even greater increases in expression in PD1+CD4+ T cells by 754%,
932%, 993%, 1239% and 2096%, respectively (Figure 3.4C).

3.3 In silico analysis of miRNAs that may bind to the 3’ UTR
of PD1, TIM3 and BTLA
To discover miRNAs that may bind to the 3’ UTR of PD1, TIM3 and BTLA an in silico
database search was conducted using miRanda, TargetScan and PicTar. Of note, miR-28
and miR-150 have significant complementarity to all 3 inhibitory immunoreceptors, and
miR-103 and miR-107 were complementary to PD1 and BTLA (Table 3.1 and Figure
3.5). Therefore, in accordance with the miRNA array data, these 4 miRNAs were chosen
as candidates for further study.

3.4 miR-28 and miR-107 silence PD1 through its 3’ UTR
To determine whether any of the 4 candidates could silence PD1 through its 3’ UTR, a
dual luciferase assay was conducted. The 3’ UTR of PD1 was amplified from WT
C57BL/6 lymph nodes and ligated into the pmirGLO Dual Luciferase miRNA Target
Expression Vector (Promega, USA) directly downstream of firefly luciferase. B16F10
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Figure 3.2 19 miRNAs have significantly altered expression between CD4+PD1- and
CD4+PD1+ T cells isolated from tumor-bearing mice. Using the Affymetrix GeneChip
3.0 miRNA Array a total of 1,966 mouse miRNAs were analyzed in PD1+ and PD1CD4+ T cells. The heat maps represent 19 miRNAs with a fold change greater than +/- 2
between CD4+PD1- and CD4+PD1+ samples. The left heat map shows fold changes
between CD4+PD1- and CD4+PD1+ T cells from three individual experiments, and the
right heat map shows the average fold-change from all samples.
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miRNA array between CD4+PD1+ and CD4+PD1- T cells
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Figure 3.3 Fold changes in miRNA expression between PD1+CD4+ and PD1-CD4+ T
cells determined by the miRNA array and qPCR data. In order to discover
discrepancies between the miRNA array and qPCR data, fold-changes were compared
and only the miRNAs with equal trends were considered for further study. The data
shown are representative of three independent experiments.
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Figure 3.4 RT-qPCR confirms 11 significantly up- and downregulated miRNAs
discovered in the microRNA array. (A) Significantly downregulated miRNAs in
PD1+CD4+ T cells that show an equal trend between the miRNA array and qPCR data.
(B-C) Significantly upregulated miRNAs in PD1+CD4+ T cells that show an equal trend
between the miRNA array and qPCR data. Significance (p < 0.05) between PD1- and
PD1+CD4+ T cells was determined using an unpaired student’s T test (* = p < 0.05, ** =
p < 0.01 and *** = p < 0.001). Data are representative of three independent experiments.
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Table 3.1 miRNA candidates that may silence PD1, TIM3 and BTLA in various
combinations. In silico analysis using miRanda, TargetScan and PicTar to discover
miRNA candidates that may silence PD1, TIM3 and BTLA in various combinations. The
bolded miRNAs represent candidates that were chosen for further study.
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miRNA candidates that may silence PD1, TIM3 and BTLA in various combinations

PD1 & TIM3
mmu-miR-28
mmu-miR-150
mmu-miR-708
mmu-miR-370

PD1 & BTLA
mmu-miR-28
mmu-miR-150
mmu-miR-708
mmu-miR-103
mmu-miR-107
mmu-miR-154
mmu-miR-320

TIM3 & BTLA
mmu-miR-28
mmu-miR-150
mmu-miR-708
mmu-miR-544

PD1, TIM3 & BTLA
mmu-miR-28
mmu-miR-150
mmu-miR-708
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Figure 3.5 Candidate miRNA alignment on the 3’ UTRs of PD1, BTLA and TIM3
mRNA. The theoretical bindings sites for miR-28, miR-150 and miR-103/107 on the (A)
PD1, (B) BTLA and (C) TIM3 3’ UTR. Each miRNA-mRNA combination displays the
miRNA, murine 3’ UTR and human 3’ UTR sequences from top to bottom. Since the
sequences for miR-103 and miR-107 differ by only one nucleotide, the * represents a G
and C, respectively. The vertical black lines and red nucleotides represent base-pairing
between the miRNA and the murine (mmu) 3’ UTR, while the red nucleotides in the
human (hsa) 3’ UTR are complementary to the miRNA. The number in the bracket
denotes the distance in nucleotides from the start of the 3’ UTR to the start of the miRNA
seed region.
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cells were used to transfect the dual luciferase plasmid with miRNA mimics or control
miRNA, and 24 hours later cells were collected and analyzed through a luminometer for
firefly and renilla luciferase activity. Data showed (Figure 3.6) that miR-28 and miR-107
reduced luciferase activity to 50 and 40%, respectively, while miR-150 and miR-103 had
no regulatory effect on the luciferase activity indicating that miR-28 and miR-107 bind to
the 3’ UTR of the PD1 gene.

3.5 Anti-CD3e, but not IFNγ, upregulates PD1 and BTLA
expression in vitro
In order to determine if the miRNA expression is altered as a response to PD1
upregulation, rather than a causation, an in vitro system needed to be discovered that
could upregulate inhibitory immunoreceptor expression. Two methods were attempted,
which involved culturing lymphocytes on anti-CD3e coated plates or exposing the cells
to IFNγ. CD3e stimulation alone, without a CD28 co-activation signal causes the T cell to
undergo anergy, a very similar process to T cell exhaustion. As well, previous research
has shown that IFNγ upregulated PD-L1 expression on human uveal melanoma cells,
thus we were curious to discover if IFNγ affects PD1 expression on T cells [105].
Initially, 2 million lymphocytes were plated in 24 well plates that were coated with 0, 1,
10 or 25 µg/mL of anti-CD3e overnight or exposed to 0, 1, 5, 10 or 20 ng/mL of IFNγ in
the cell culture medium. Cells were cultured for 24 hours and analyzed by flow
cytometry. Anti-CD3e treatment significantly increased PD1 and BTLA expression on
CD4+ and CD8+ T cells in a dose depending manner (Figure 3.7). On the other hand,
IFNγ had no observable effect on inhibitory immunoreceptor expression (Figure 3.8).
Therefore, 10 µg/mL of anti-CD3e was used for subsequent experiments.
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Figure 3.6 miR-28 and miR-107 bind to and silence the PD1 3’ UTR. Dual Luciferase
Assay of pmirGLO Plasmid with PD1 3’ UTR insert and miRNA mimics. B16F10 cells
were transfected with the PD1 3’ UTR dual luciferase plasmid and either miRNA mimic
or mimic control. Luciferase Activity was measured with a luminometer and normalized
to mimic control. A one-way ANOVA followed by a Dunnett’s multiple comparison test
between miRNA mimic and control was used for statistical analysis, significance was
determined if p < 0.05. The data shown represent three independent experiments.

48

Dual Luciferase Assay of miRNA and pmirGLO with
PD1 3' UTR insert
140

% Luciferase Activity
(firefly:renilla)

120
100
80

*

*

60
40
20
0
mimic control

miR-28

miR-150

miR-103

miR-107

49

Figure 3.7 Anti-CD3e treatment increases PD1 and BTLA expression in a dosedependent manner. Percent of PD1, TIM3 and BTLA expression on viable CD4+ or
CD8+ T cells after treatment with various concentrations of anti-CD3e. Lymphocytes
were isolated from lymph nodes of WT C57BL/6 mice and 2 million cells/well were
plated in a 24-well plate, which was coated with various concentrations of anti-CD3e
antibody the night before. 24 hours after plating, cells were stained with Viability Dye
eFluor 506, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE and BTLA-APC,
and analyzed by flow cytometry. (A) PD1 expression (B) TIM3 expression (C) BTLA
expression. For both T cell subtypes, a one-way ANOVA followed by a Dunnett’s
multiple comparison test was used to compare immunoreceptor expression alterations
between treatment and non-treatment with anti-CD3e. Signification was determined if p <
0.05 (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001). The data shown are representative
of three independent experiments.
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Figure 3.8 IFNγ treatment has no effect on PD1, TIM3 or BTLA expression. Percent
of PD1, TIM3 and BTLA expression on viable CD4+ or CD8+ T cells after exposure to
various concentrations of IFNγ. Lymphocytes were isolated from lymph nodes of WT
C57BL/6 mice and 2 million cells/well were plated in a 24-well plate. 0, 1, 5, 10 or 20
ng/mL of IFNγ was added to the wells and cells were incubated at 37 °C for 24 hours.
Flow cytometric analysis was performed after cells were stained with Viability Dye
eFluor 506, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE and BTLA-APC.
(A) PD1 expression (B) TIM3 expression (C) BTLA expression. For both T cell
subtypes, a one-way ANOVA followed by a Dunnett’s multiple comparison test was used
to compare immunoreceptor expression alterations between treatment and non-treatment
with IFNγ. The data shown are representative of three independent experiments.

52

A

PD1 Expression on T cells incubated with IFNγ

% PD1 expression

5
4
3
CD4+

2

CD8+

1
0
0

1

% TIM3 expression

B

10

20

8
7
6
5
4
3
2
1
0

CD4+
CD8+

0

1

C
% BTLA expression

5
IFNγ (ng/mL)

5
IFNγ (ng/mL)

10

20

40
35
30
25
20
15
10
5
0

CD4+
CD8+

0

1

5
IFNγ (ng/mL)

10

20

53

3.6 miR-28, miR-150, miR-103 and miR-107 show
decreased expression after anti-CD3e treatment
To determine if the miRNA levels discovered in CD4+PD1+ T cells from B16F10 tumorbearing mice were a result of increased PD1 expression, 2 million lymphocytes were
plated per well in a 24 well plate coated with anti-CD3e (10 µg/mL). 24 hours later
lymphocytes were collected and CD4+ T cells purified using MACS beads. RNA was
isolated and the expression of the 4 candidate miRNAs was measured with RT-qPCR.
Expression was normalized to non- stimulated CD4+ T cells, resulting in a significant
down regulation of the 4 candidate miRNAs. miR-28, miR-150, miR-103 and miR-107
were downregulated to 41.3%, 22.2%, 51.9% and 42.8%, respectively (Figure 3.9).

3.7 miR-28 and miR-107 inhibitors increase PD1
expression in CD4+ T cells in vitro
The next step was to reevaluate how these miRNAs may effect inhibitory
immunoreceptor expression in a more physiologically relevant state, by transfecting T
cells. Although my lab focuses on the immune system in cancer, no one has previously
attempted to transfect T cells, so the first step was to optimize the protocol to achieve a
high transfection efficiency and viability, and then to demonstrate the ability to
knockdown a gene. 1 µg of GAPDH-Cy3 siRNA was transfected into 2 million
lymphocytes with varying amounts of Lipofectamine 2000 or Lipofectamine RNAiMAX.
Figure 3.10 shows a representative histogram for each group, demonstrating that
Lipofectamine 2000 had a superior T cell transfection efficiency after 24 hours compared
to RNAiMax. Next, the optimal transfection ratio of siRNA (µg):Lipofectamine 2000
(µL) was determined to be 2:1, which achieved a transfection efficiency of 62.7% and
total viability of 29.8% 48 hours after transfection (Figure 3.11). To prove that the
optimized transfection efficiency resulted in gene knockdown, lymphocytes were
transfected with GAPDH siRNA, control siRNA or left alone. 48 hours later, T cells were
isolated using Pan T Cell Isolation Kit II MACS beads and RNA was purified for use in
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Figure 3.9 miR-28, miR-150, miR-103 and miR-107 decrease expression after PD1
upregulation mediated by anti-CD3e binding. Altered miRNA expression in CD4+ T
cells treated with anti-CD3e. Two million lymphocytes were collected from WT
C57BL/6 lymph nodes and plated in a 24 well plate coated with 10 µg/mL of anti-CD3e.
24 hours later CD4+ T cells were isolate using MACS beads and total RNA, including
miRNAs, were isolated and used for real time RT-qPCR to determine the changes in
miR-28, miR-150, miR-103 and miR-107 expression after PD1 upregulation mediated by
anti-CD3e. Significance (p < 0.05) was determined using an unpaired student’s T test.
Data are representative of three independent experiments. * = p < 0.05, ** = p < 0.01 and
*** = p < 0.001.
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Figure 3.10 Lipofectamine 2000 demonstrates greater transfection efficiency in T
cells comparted to Lipofectamine. 2 million lymphocytes were plated in 24 well plates
and 1 µg of GAPDH-Cy3 siRNA was transfected for 24 hours using a 1:2, 1:4, 1:6 or 1:8
ratio of siRNA (µg):transfection reagent (µL) and transfection efficiency was observed
using flow cytometry. Data are displayed as a histogram showing representative
efficiency of three independent experiments of GAPDH-Cy3 siRNA transfection into
viable CD3+ T cells.
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Figure 3.11 A 2:1 ratio of siRNA (µg):Lipofectamine 2000 (µL) provides the optimal
T cell transfection efficiency and total viability. 2 million lymphocytes from the lymph
nodes of WT C57BL/6 were plated in a 24 well plate and transfected with 1 µg/mL of
GAPDH-Cy3 siRNA while varying the amounts of Lipofectamine 2000. 48 hours after
transfection cells were stained with Viability Dye eFluor 506 and CD3-FITC. Flow
cytometric analysis was performed to determine the (A) transfection efficiency by
measuring Cy3 fluorescence in viable CD3+ T cells and (B) total viability by gating on
CD3+ T cells. The data shown are representative of three independent experiments.

59

A

Transfection efficienciy of Cy3-labelled GAPDH siRNA using
varying ratios of siRNA (µg):Lipofectamine (µL)

% Transfection Efficiency

80
70
60
50
40

30
20
10
0
1:6

B

1:4

1:2

1:1

2:1

Total Viability after Cy3-labelled GAPDH siRNA transfection using
varying ratios of siRNA (µg):Lipofectamine (µL)

% Total Viability

60
50
40
30
20
10
0
1:6

1:4

1:2

1:1

2:1

60

real time RT-qPCR. The data showed that using the GAPDH siRNA, gene expression
was silenced approximately 75%, demonstrating the effectiveness of the T cell
transfection protocol (Figure 3.12).
Since PD1 expression is low on naïve T cells (Figure 3.1B), a 4 day anti-CD3e
treatment was used to induce PD1 expression and to determine if reduction of intrinsic
miRNA could increase anti-CD3e stimulated PD1 expression. Two million lymphocytes,
collected from the lymph nodes of WT C57BL/6 mice, were plated in a 24 well plate and
transfected with miRNA inhibitors for 48 hours using a 2:1 ratio of siRNA:Lipofectamine
2000 (µg:µL). After a 4 day exposure to anti-CD3e, cells were collected and stained for
PD1, CD4, CD8 and viability. Compared to miRNA inhibitor control, anti-miR-28 and
anti-miR-107 transfected CD4+ T cells demonstrated a 15.66% and 16.39% fold-increase,
respectively (Figure 3.13A). CD8+ T cells displayed a similar trend with 27.38%, 26.15%
and 33.77% fold-increase in miR-28, miR-150 and miR-107, respectively (Figure 3.13B).
miR-103 transfection had no effect on PD1 expression in both CD4+ and CD8+ T cells
(Figure 3.13A and B).

3.8 miR-28 and miR-107 mimic transfection has no effect
on proliferation in CD4+ T cells.
To investigate the therapeutic potential of miR-28 and miR-107, lymphocytes were
transfected with 1 µg of mimic control, miR-28 or miR-107 for 48 hours and stained with
CFSE before a 4 day incubation on anti-CD3e coated plates (10 µg/mL). CD4+ T cells
were isolated using MACS beads and PD1 expression was analyzed to determine if these
miRNA mimics can silence PD1 in T cells in vitro. While miR-107 had no significant
effect on PD1 expression, miR-28 mimic reduced PD1 expression from 80.3% to 70.9%
(Figure 3.14). To investigate whether this silencing resulted in altered proliferation the
CD4+ T cells were analyzed using flow cytometry with CFSE staining. By gating on
CFSElow cells, the proportion of proliferating cells was analyzed between miRNA mimics
and control (Figure 3.15A). No significant difference in the percent of proliferating cells
was found between the control or miR-28/miR-107 mimic transfection (Figure 3.15B).
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Figure 3.12 A 2:1 ratio of GAPDH siRNA (µg):Lipofectamine 2000 (µL) results in a
75% knockdown in GAPDH expression 48 hours after transfection. Using 1 µg of
GAPDH siRNA or control siRNA with a 2:1 ratio of siRNA:Lipofectamine 2000
(µg:µL), 2 million lymphocytes isolated from the lymph nodes of WT C57BL/6 were
transfected in a 24 well plate. 48 hours after transfection, T cells were purified and RNA
was isolated for use in real time qPCR with oligomers for GAPDH and β-actin (reference
gene). A one-way ANOVA and Dunnett’s multiple comparison test was used to compare
the control and GAPDH siRNA to the non-transfected cells (* = p <0.05). Data are
representative of four independent experiments.
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Figure 3.13 miR-28, miR-150 and miR-107 inhibitors increase PD1 expression after
T cell transfection and incubation on anti-CD3e coated plates. 2 million lymphocytes,
collected from lymph nodes of WT C57BL/6 mice, were plated per well in a 24 well
plate and transfected with 1 µg of miRNA inhibitor or inhibitor control. Cells were
transfected at 37 °C for 48 hours before being transferred to a 24 well plate coated with
10 µg/mL of anti-CD3e for 4 days. Flow cytometric analysis was performed to determine
the miRNAs ability to alter expression of PD1 on (A) CD4+ and (B) CD8+ T cells. A oneway ANOVA test was used to determine significance (p < 0.05), significance between
the miRNA inhibitors and inhibitor control was determined with a Dunnett’s multiple
comparison test. Bars marked with a ** denote p < 0.01 and *** denote p < 0.001. The
data shown are representative of three independent experiments.
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Figure 3.14 miR-28 significantly silences PD1 expression in CD4+ T cells after
transfection and incubation on anti-CD3e coated plates. Lymphocytes were isolated
from lymph nodes of WT C57BL/6 mice and 2 million cells were plated per well in a 24
well plate. 1 µg of miRNA mimic or mimic control were transfected and cells were
transfected at 37 °C for 48 hours before being transferred to a 24 well plate coated with
10 µg/mL of anti-CD3e for 4 days. CD4+ T cells were isolated using MACS beads and
flow cytometric analysis was performed to determine the miRNAs ability to silence
expression of PD1 in T cells. Significance was determined using a one-way ANOVA
followed by a Dunnett’s multiple comparison test between control and each miRNA
mimic (*** = p < 0.001). Data are representative of two independent experiments.
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Figure 3.15 miR-28 and miR-107 have no effect on cell proliferation induced by
anti-CD3e stimulation. 2 million lymphocytes, isolated from lymph nodes of WT
C57BL/6 mice, were plated per well in a 24 well plate. 1 µg of miRNA mimic or mimic
control were transfected and cells were transfected at 37 °C for 48 hours. Cells were then
stained with CFSE then plated on anti-CD3e coated plates (10 µg/mL) for 4 days before
CD4+ T cell isolation, PD1-PerCP eFluor710 staining and flow cytometric analysis. (A) 4
day CFSE histogram showing the proliferation profiles of mimic control, miR-28 and
miR-107 transfected T cells. (B) Quantification of the percentage of proliferated T cells
(CFSElow). Significance (p < 0.05) was determined using a one-way ANOVA followed
by a Tukey’s post-hoc test. Data shown are representative of four independent
experiments.
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3.9 miR-28 mimic transfection reduces anti-CD3e induced
early and late apoptosis in CD4+ T cells
The last experiment was designed to determine if transfection of CD4+ T cells with
miRNA mimic could reduce apoptosis in activated T cells. Lymphocytes were transfected
as described in 3.8, however, no cells were stained with CFSE before 4 day incubation on
anti-CD3e coated plates. After incubation, CD4+ T cells were isolated and stained for
PD1, Viability Dye eFluor 506 and Annexin V-FITC. Cells that stain eFluor506AnnexinV+ are in early apoptosis, while cells that stain eFluor506+AnnexinV+ are in late
apoptosis. miR-107 transfection had a significantly increased percentage of viable CD4+
T cells (15.13% > 4.22%) and decreased percentage of late apoptotic cells (68.73% <
81.87%) over control (Figure 3.16A and B). miR-28 transfected CD4+ T cells displayed
even greater reductions in apoptosis compared to control: viability increased from 4.22%
to 29.83%, early apoptosis decreased from 12.07% to 5.62% and late apoptosis decreased
from 81.87% to 61.37% (Figure 3.16A and B).
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Figure 3.16 miR-28 mimic transfection significantly reduces the percentage of cells
in early and late apoptosis caused by prolonged anti-CD3e activation. Lymphocytes
were isolated from lymph nodes of WT C57BL/6 mice and 2 million T cells were plated
per well in a 24 well plate. 1 µg of miRNA mimic or mimic control were transfected and
cells were cultured at 37 °C for 48 hours before being plated on anti-CD3e coated plates
(10 µg/mL) for 4 days. Using CD4 MACS beads, CD4+ T cells ere purified and stained
with PD1-PerCP eFluor710, viability dye eFluor 506 and annexin V FITC and analyzed
by flow cytometry. (A) Dot plot showing viable (eFluor506-annexinV-), early apoptotic
(eFluor506-annexinV+) and late apoptotic (eFluor506+annexinV+) CD4+ T cells after
transfection with mimic control, miR-28 or miR-107 and 4 day treatment with anti-CD3e.
(B) Quantification of the viable, early and late apoptotic CD4+ T cells. Within each stage
of apoptosis, the miRNA mimics and controls were compared using a one-way ANOVA
followed by Tukey’s post-hoc test (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001).
Data are representative of three independent experiments.
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Chapter 4

4

Discussion

4.1 Discussion
The key findings from this study are: 1) miR-28, miR-150 and miR-151-5p are
downregulated; and miR-let-7e, miR-103, miR-107, miR-27a, miR-23a, miR-21, miR155 and miR-146a are upregulated in PD1+CD4+ T cells, 2) in silico data reveal that miR28 and miR-150 should bind to the 3’ UTRs of PD1, TIM3 and BTLA, while miR-103
and miR-107 bind to PD1 and BTLA, 3) anti-CD3e treatment upregulates PD1
expression and decreases expression of all 4 candidate miRNAs, 4) miR-28 and miR-107
bind to the 3’ UTR of PD1 and silence PD1 expression, while lymphocyte transfection
with miR-28, miR-150 and miR-107 inhibitors increase PD1 expression on T cells and 5)
although no differences in proliferation were seen in miRNA mimic transfected CD4+ T
cells, miR-28 and miR-107 transfection lead to reduced early and late activation-induced
apoptosis.
miRNAs are quietly emerging as new therapeutic markers for use in various
diseases. Currently, two miRNA based therapeutics are in clinical trials that use a LNA
anti-miR-122, miravirsen, against hepatitis C [106] or liposome-based miR-34a mimic,
MRX34, against a multitude of cancers [107]. Although it is exciting to see the
emergence of a new class of drugs for use in cancer therapy, miRNAs have their
limitations. Although a miRNA may be able to target multiple genes in pro-tumoral
pathways to elicit a broad anti-tumor responses, the possibility also exists for negative
off-target effects [108]. As well, a miRNA may have separate targets in different cell
types, i.e. cancer vs an immune cell, which can be beneficial or harmful as a therapeutic
approach.
One of the most important factors that contribute top success of RNAi therapies is
the ability to deliver small RNA molecules inside the cell. A high transfection efficiency
is necessary to ensure that the RNA has a significant effect on cell function, while a low
toxicity is important to ensure that the therapeutic benefits of gene silencing outweigh the
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cell loss due to transfection. T cells are difficult to transfect, and currently the most
popular method to transfect primary human and murine T cells with siRNA/miRNA in
vitro is electroporation. Electroporation uses an electric field to disrupt the cell membrane
and allow RNA to enter the cell [109]. The industrial leader in T cell electroporation is
Lonza with the Lonza Nucleofector II electroporation system and Amaxa Nucleofector
Kits. When comparing homemade buffers to the ones found in the Amaxa Nucleofector
Kit for human and murine T cells, Chicaybam et al. discovered that the Amaxa kit was
superior at transfecting human T cells with approximately 45% transfection efficiency
and 70% viability. On the other hand, the homemade buffer was superior at transfecting
murine T cells with the transfection efficiency and viability at 40% and 60%, respectively
[110]. In this study, a 2:1 ratio of siRNA (µg):Lipofectamine 2000 (µL) resulted in a
greater murine T cell transfection efficiency of 62.7% and reduced total viability of
29.8% when compared to the Amaxa or homemade electroporation kits (Figure 3.11).
Overall, the lipofectamine protocol may prove more versatile since electroporation is
limited to transfecting activated T cells only; non-activated T cells demonstrated below
10% transfection efficiency and viability [110]. Other mentionable factors that lead to
increased viability were the addition of 2-ME, a reducing agent that prevents oxygen
radical buildup, and absence of penicillin or streptomycin in the transfection medium as
per manufacturer’s instructions.
Another issue that arose in this study was naturally low expression of PD1 on T
cells from WT C57BL/6 mice. In order to demonstrate silencing of PD1, and how that
affects the function of CD4+ T cells, PD1 expression needed to be induced. One study
conducted by Park et al. generated γ-retroviral vectors for expression of artificial
miRNAs and transfected the vector into human lymphocytes along with one for
constitutive expression of PD1 [111]. Of importance, miR-150 was able to silence vectorinduced PD1 expression by approximately 90% 5 days after lymphocyte culture. It must
be kept in mind, however, that the artificial vectors were created by designing a hybrid
RNA molecule that resembles the endogenous miRNA with the stem sequence replaced
by a siRNA against PD1. Consequently, the large silencing effect seen may be overexaggerated by the presence of PD1 siRNA. As well, since human T cells were used for
transduction and the analysis was conducted using flow cytometry, it is unknown whether
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the miR-150 directly bound the PD1 transcript or indirectly silenced PD1. Therefore, this
research project is the first to demonstrate that not only do miR-28 and miR-107 directly
regulate PD1 expression through its 3’ UTR, but miR-150 also indirectly silences PD1 in
T cells through some unknown pathway. In order to avoid T cell transfection with
miRNAs and a large vector, it was decided to use other means to induce PD1 expression.
Anti-CD3e was chosen based on previous research that successfully used anti-CD3e to
induced PD1 expression and T cell anergy on CD4+ T cells to test the therapeutic effects
of PD1 siRNA [29]. IFNγ was tested based on curiosity since it can induce PD-L1
expression on B16 melanoma cells and other cancers [112-114].
In the past decade miRNA research has exploded and been explored as diagnostic,
prognostic and therapeutic makers, but to date very little miRNA research exists on PD1,
and none exist sin the scope of melanoma therapy. One of the first miRNA and PD1
papers, written by Iliopoulos et al., discovered that miR-21 was significantly upregulated
upon ovalbumin stimulation in T cells, and that inhibition of PD1 with siRNA or
knockout mice increased miR-21 expression [115]. As well, that miR-21 was found to
control PDCD4, an intracellular protein with similar inhibitory effects as PD1 [115].
Recent studies on miR-21 and T cell activation demonstrate increased miR-21 expression
in active or differentiated T cells [116, 117]. In this study, miR-21 was increased 10-fold
in PD1+CD4+ T cells, which is comparable to the miR-21 expression before and after
ovalbumin stimulation. This paints the picture that tumor-specific T cells in the tumor
microenvironment would activate, upregulate miR-21 and PD1, which results in PD1
silencing miR-21 and inducing the tumor suppressor targets of miR-21: PDCD4, PTEN
and Bcl-2 [118]. In terms of T cell exhaustion, high miR-21 expression is considered
therapeutic as it prevents upregulation of suppressor genes in the T cells; however, for
many different cancers cells miR-21 is considered an oncomir as it supports continued
cell growth. Therefore, if miRNA hope to have a place in immunotherapy then cell
specific delivery techniques need to be in place to ensure removal of immune suppression
in T cells while preventing miR-21-induced tumor-suppressor silencing in cancer cells.
Moreover, it seems that miR-21 has altered regulating roles depending on the
differentiation status of the CD4+ T cell. Memory T cells have miR-21 function antiapoptotically, while miR-21 in newly activated T cells silence CCR7 and modulates
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lymphoid organ migration [119]. Therefore, specific delivery of miRNA into T cells may
also be limited by specific subset delivery.
Other miRNAs of relevance in cancer immunotherapy are miR-150, miR-155 and
miR146a. In this study, miR-150 expression was significantly decreased in PD1+ T cells
and shown to indirectly regulate PD1 expression. miR-150 mimic displayed no direct
silencing of the 3’ UTR of PD1 in the dual luciferase assay, but miR-150 inhibitors
increased PD1 expression in T cells. Other studies reveal that miR-150 is downregulated
in T cell lymphoma and colorectal cancer and is a tumor suppressor by targeting c-Myb
[57, 120]. Conversely, in bladder cancer miR-150 is upregulated which results in lower
PDCD4 expression [121]. Thus, miR-150 can be seen as a double edge sword as it acts as
a tumor suppressor by silencing the oncogene c-Myb, while at the same time acting as an
oncomir by silencing PDCD4 and increasing cell invasiveness. Overall, this strengthens
the idea that miRNA regulation can be specific for different cell types and disease states,
and therefore results from other studies on miRNAs and cancer may not necessarily
translate to the field of melanoma immunotherapy.
miR-155 and miR-146a were the most altered in PD1+ cells with approximately
12 and 21 fold increase, respectively. miR-155 is an interesting miRNA as it has been
shown to silence CTLA4 [122], and miR-155 knockout mice are highly resistant to
autoimmunity, which is reversed in miR-155(-/-)Pdcd1(-/-) double knockout mice [123].
Upon T cell activation miR-155 has been shown to increase in expression and silence
suppressor of cytokine signaling 1 (SOCS1) [124]. Thus, miR-155 is normally induced
upon activated T cells and has two silencing pathways to support cell proliferation and
maturation. miR-146a is normally low in naïve human T cells and is induced upon T cell
receptor stimulation [125, 126]. Moreover, miR-146a expression is correlated to
decreases in activation-induced cell death by targeting fas-associated death domain
(FADD) [125]. However, similar to miR-150, miR-146a acts as a double edge sword to T
cell growth and survival by targeting and silencing IL-2 through IRAK1 and TRAF6
[125] and inhibiting NF-κB activity, thus preventing hyperactivity in antigenic responses
[126].
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miR-23a recently has become a popular regulator of cytoxicity in CD8+ T cells.
TGF-β derived from tumors tissue upregulates miR-23a in CD8+ T cells resulting in
silencing of BLIMP-1, a promoter of cytotoxicity. From this discovery an effective
adoptive cell therapy was created in mice by transfecting tumor-specific CD8+ T cells
with miR-23a inhibitor, resulting in reduced tumor growth [127]. Another study on miR23a in CD8+ T cells also found that increased miR-23a expression induced attenuation of
cytotoxicity, which may be due to silencing of lysosomal-associated membrane protein 1
(LAMP1) [128]. In the same study, miR-27a was shown to directly silence IFNγ acting as
a partner to miR-23a to lower cytotoxicity upon TGF-β stimulation. Although increases
in miR-23a and miR-27a expression were observed in CD4+PD1+ T cells, it is difficult to
tell if miR-23a and miR-27a exhibit suppressive functions in CD4+ T cells. Studies so far
have only looked at miR-23a and miR-27a in CD8+ T cells by investigating changes in
cytotoxicity, and therefore no data is available to confirm if these miRNAs affect CD4+ T
cell function.
The previously mentioned miRNAs have been studied extensively in T cells and
in cancer, and they demonstrate the delicate nature of a miRNA therapy in T cells. Due to
the dual and opposite functions that miRNA can elicit, some miRNAs may have
undesired off-target effects that can reduce the therapeutic benefits of miRNA regulation.
Moreover, miRNAs can alter function depending on the cell-type transfected, thus
efficient targeted delivery may be mandatory in order to observe functional changes or
reduce off-target effects. Moving forward, the aim of this research was to discover
miRNA that silence PD1 expression, which is why miR-28, miR-150, miR-103 and miR107 were chosen for further study.
To date, almost no papers exist that focus on the function of miR-103 and miR107 in T cells. One study, although focused on triple-negative breast cancer, analyzed the
prognostic performance of miRNAs in 58 patients and found that lymph node status was
the only clinicopathological factors that was significant in predicting poor prognosis. As
well, that poor prognosis and distant metastasis were correlated to high intratumoral miR103 and miR-107 expression [129]. Other research groups compared serum miRNA
levels between breast cancer and healthy patients, and found elevated miR-107 levels
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[130, 131]. Similar results were seen in lung and pancreatic cancer, where miR-107 was
associated with tumor growth and decreased lung cancer survival and miR-103 was
associated with risk of pancreatic cancer, however, miR-107 and miR-103 were lower in
cancerous tissue [132, 133]. The prognostic potential of these miRNAs is not limited to
disease progression, but extends towards therapeutic outcome prediction. Another study
aimed to detect if miRNA levels can be used to predict outcomes of chemotherapy.
Patients with metastatic colorectal cancer were treated with chemotherapy and
intratumoral miRNA levels were measured. It was discovered that high miR-107
correlated to overall survival [134]. Plenty of evidence exists to confirm the prognostic
potential of miR-103 and miR-107, however it appears expression changes seem to differ
depending on the disease. This may be due to the fact that, similar to miR-150 and miR146a, both miR-103 and miR-107 can act as oncomirs or tumor suppressive miRNAs by
targeting DICER, PTEN or CCND1, CDK8, MCL1, PD1 respectively [134-137]. In this
study, miR-103 and miR-107 was approximately 3-fold increased in PD1+CD4+ T cells
over PD1-CD4+ T cells isolated from tumor-bearing mice, however, when CD4+ T cells
are stimulated with anti-CD3e for 24 hours expression of miR-103 and miR-107
decreased. Therefore, the increased miR-103 and miR-107 expression observed in PD1+
cells may either be a result of the presence of melanoma or a marker of exhausted T cells.
miR-28 became the candidate miRNA that fulfilled the objectives of this study.
Reductions were seen in PD1+CD4+ T cells, miR-28 was shown to silence the 3’ UTR of
PD1 and use of miR-28 mimic and inhibitors altered PD1 expression resulting in the most
significant decrease in activation-induced cell death. Current research involving miR-28
and T cell disease primarily focuses on HIV infection, but one research article on natural
killer/T-cell lymphoma (NKTL) demonstrated reductions in miR-28 expression in
cancerous cells. However, transfection with miR-28 mimic reduced cell growth in NKTL
cells [138]. When looking at a different immune cell, the B cell, miR-28 expression is
reduced in B cell lymphoma and reexpression of this miRNA leads to impaired cell
proliferation through MAD2L1, a component of the cell cycle through mitotic spindle
coordination [139]. With focus on a non-immune cell related cancer, clear cell renal cell
carcinoma, miR-28 mimic transfection was shown to weaken mitotic checkpoint
activation and induce chromosomal instability by also targeting MAD2L1 [140].

78

Although miR-28 reexpression in my study proved beneficial to CD4+ T cells, these
contradicting results illustrate the necessity to further understand altered miRNA
expression between subsets of T cells (CD4+ vs CD8+ or NK cells), as well as between
whether the T cell is the origin of the disease or merely a combatant in the fight against
cancer. In the end, the fact cannot be ignored that miR-28 is downregulated in a multitude
of cancerous immune cells and tissues, and maintains a tumor suppressive role by
reducing growth of cancerous cells through MAD2L1. This research project expands the
role of miR-28 as an indirect tumor suppressor by preventing cell death in activated CD4+
T cells through silenced PD1 expression.
In conclusion, miR-28 and miR-107 were shown to silence PD1 through its 3’
UTR, and transfection with miR-28 and miR-107 mimics reduced early and late
activation-induced cell death. Therefore, miR-28 and miR-107 remain as great candidates
to act as a silencing therapeutic agent against PD1. Ultimately, this novel research
demonstrates a potential role for miR-28 and miR-107 in regulating T cell responses to
cancer. With the success that anti-PD1 antibodies are having in clinical trials,
investigating how miRNA regulates PD1 in T cells is necessary to expand our
understanding of immunoregulatory pathways for prognostic and therapeutic purposes.

4.2 Future Directions
In this thesis, the microarray profile between PD1+/- CD4+ T cell allowed us to discover,
for the first time, miRNAs from a murine melanoma model that alter expression based on
PD1 status. With a focus towards reversing T cell suppression caused by melanoma,
various miRNAs were highlighted as candidates to silence PD1 and other T cell
exhaustion markers. However, more can be done to further understand how miR-28 and
miR-107 regulate T cell function in vitro. For instance, an ELISA or intracellular flow
cytometry staining of IFNγ, TNFα and IL-2 after miRNA mimic/inhibitor transfection is
recommended to determine if these miRNA can increase anti-tumoral cytokine secretion.
Moreover, to understand how miR-28 and miR-107 affect CD8-mediated cytotoxicity, a
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cytotoxic T lymphocyte killing assay can be performed using miRNA-transfected CD8+
T cells and labelled B16F10 cells.
In order to determine if any of the candidate miRNA affect TIM3 or BTLA
expression, the pmirGLO dual luciferase assay should be utilized in tandem with miRNA
mimic/inhibitor transfection of T cells. The dual luciferase assay displays miRNAs that
directly bind to the 3’ UTR, while in vitro T cell transfection provides a more
physiological relevant microenvironment to confirm direct and indirect expression
changes.
The final step for this study would involve a translation to in vivo murine
melanoma model to discover if these miRNAs can improve T cell function against
B16F10 melanoma. Evidence has shown that miRNAs may have opposing functions in
different cell types, therefore a T cell specific delivery system is necessary to minimize
the off-target effects of the miRNA candidates. Many new methods are coming to fruition
by using CD7 antibody conjugated to oligo-9-arginine (scFvCD7-9R), CD7 antibody
conjugated to chitosan or RNA-secreting primary B lymphocytes to deliver RNA into T
cells [124, 141-143]. Alternatively, to avoid the barrier of specific T cell gene delivery in
vivo, current in vitro methods can be used to transfect T cells for adoptive cell transfer. If
altering expression of miRNAs, such as miR-28 and miR-107, in T cells can demonstrate
control of T cell function towards melanoma in a mouse model, it would warrant
translation to human T lymphocytes from melanoma patients.
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